accord
air
pollut
includ
indoor
outdoor
sourc
biggest
environment
caus
death
worldwid
contribut
million
prematur
death
everi
year
impact
vulner
poor
major
environment
risk
factor
demonstr
women
children
live
lmic
highest
exposur
household
air
pollut
especi
indoor
biomass
fuel
combust
global
nearli
billion
peopl
use
biomass
fuel
coal
wood
dung
crop
residu
domest
energi
product
either
cook
heat
light
home
chimney
ventil
smoke
exposur
toxic
amount
combustionrel
pollut
associ
variou
respiratori
diseas
includ
lower
respiratori
infect
lrti
children
interestingli
use
biomass
fuel
vari
locat
cultur
socioeconom
statu
determin
exposur
result
health
risk
effect
indoor
air
pollut
iap
children
respiratori
health
develop
countri
much
less
extrem
vari
observ
poorer
home
develop
world
howev
increas
evid
sourc
iap
eg
tobacco
smoke
exposur
contribut
respiratori
diseas
children
industri
countri
gauderman
et
al
show
advers
effect
air
pollut
lung
develop
children
year
old
lead
clinic
signific
deficit
attain
reach
adulthood
iap
equal
greater
impact
human
health
outdoor
pollut
associ
mani
health
effect
includ
acut
chronic
respiratori
system
disord
particularli
cardiovascular
main
reason
amount
time
peopl
especi
women
children
spend
indoor
wide
rang
household
emiss
sourc
increas
concentr
toxic
pollut
indoor
compar
outdoor
mani
pollut
eg
biolog
pollut
formaldehyd
volatil
organ
compound
concentr
higher
indoor
outdoor
import
sourc
indoor
pollut
tobacco
smoke
exposur
household
cleanser
mold
mildew
burn
incens
chemic
aromat
candl
mosquito
coil
howev
limit
factor
inform
indoor
pollut
difficult
collect
outdoor
pollut
pollut
concentr
must
measur
separ
differ
hous
assum
observ
made
short
space
time
even
singl
occas
repres
habitu
exposur
diseas
caus
iap
impos
great
econom
cost
public
health
calcul
peopl
spend
time
indoor
either
home
school
offic
children
averag
spend
hour
insid
home
also
pregnant
women
spend
time
insid
home
therefor
iap
exposur
may
also
critic
prenat
period
worldwid
environment
pollut
appreci
place
quantifi
caus
diseas
howev
given
lung
diseas
lead
caus
morbid
mortal
global
effect
air
pollut
lung
health
great
interest
multipl
earli
life
factor
advers
affect
lung
function
futur
respiratori
health
recent
gray
et
al
studi
group
infant
enrol
south
african
birth
cohort
assess
determin
earli
lung
function
african
infant
found
factor
matern
smoke
matern
alcohol
household
benzen
associ
alter
earli
lung
function
addit
increas
interest
ultrafin
particl
rise
due
specif
physicochem
characterist
particl
commonli
known
nanoparticl
um
due
small
size
commonli
underestim
mani
pollut
measur
tobacco
smoke
primari
indoor
pollut
develop
develop
countri
evid
increas
respiratori
morbid
secondhand
tobacco
smoke
particularli
children
consist
although
decreas
frequenc
daili
smoker
report
last
three
decad
develop
countri
lmic
countri
remain
high
data
worldwid
reveal
high
preval
smoke
lmic
particular
asian
countri
china
india
vietnam
smoke
indoor
establish
sourc
particul
matter
pm
nicotin
carbon
monoxid
co
benzen
toxic
compound
accord
etzel
tobacco
smoke
number
one
caus
prevent
morbid
mortal
unfortun
children
expos
passiv
smoke
lower
respiratori
ill
children
without
smoker
higher
mother
smoker
addit
matern
smoke
also
encourag
children
smoke
potenti
worsen
health
also
children
live
home
smoker
like
becom
smoker
matern
smoke
pregnanc
continu
larg
public
health
problem
exposur
tobacco
smoke
often
begin
prenat
result
decreas
lung
function
birth
reduc
level
immun
increas
hospit
lrti
increas
preval
childhood
wheez
asthma
studi
estim
young
children
worldwid
expos
cigarett
smoke
home
contribut
mortal
children
becom
import
exposur
passiv
smoke
increas
risk
sever
pneumonia
children
independ
risk
factor
poor
outcom
recent
systemat
review
found
significantli
increas
risk
pneumoniarel
death
ic
among
young
children
cigarett
smoke
exposur
anoth
studi
et
al
report
children
hospit
citi
vietnam
pneumonia
household
cigarett
smoke
exposur
nitrogen
dioxid
import
compon
indoor
outdoor
air
pollut
indoor
sourc
includ
gasfuel
cooker
fire
water
heater
paraffin
heater
also
emit
small
amount
occur
tobacco
smoke
research
suggest
contribut
respiratori
symptom
children
particularli
asthmat
children
studi
suggest
increas
risk
lrti
children
expos
longterm
yet
exposur
vari
depend
proxim
children
sourc
major
difficulti
determin
health
impact
difficult
measur
person
exposur
socioeconom
statu
major
predictor
exposur
iap
level
near
home
environ
guatemala
parallel
random
control
trial
respir
studi
show
signific
reduct
sever
pneumonia
children
heavili
expos
wood
smoke
cook
chimney
stove
intervent
place
reduc
iap
addit
heinzerl
et
al
report
delay
instal
chimney
stove
intervent
associ
poorer
lung
growth
immedi
stove
instal
includ
indoor
particl
whose
import
health
proport
concentr
includ
bacteria
virus
anim
dander
hous
dust
mite
cockroach
pollen
mould
spore
mani
biolog
contamin
small
enough
inhal
import
human
health
aris
increas
preval
allerg
respiratori
diseas
children
young
adult
sensit
key
factor
develop
allergi
sensit
individu
must
expos
particular
allergen
costa
rica
ly
et
al
show
multivari
analysi
parent
report
moldmildew
child
home
p
posit
ige
respons
der
p
p
significantli
associ
airway
hyperreact
children
asthma
fungal
spore
anoth
potenti
caus
symptom
allerg
patient
also
occurr
acut
pulmonari
hemorrhag
infant
expos
toxigen
mould
anoth
exampl
infant
vulner
environment
hazard
role
formaldehyd
lower
respiratori
symptom
asthma
children
controversi
howev
sever
studi
report
associ
formaldehyd
concentr
home
school
asthma
asthma
sever
allergi
airway
inflamm
children
princip
sourc
formaldehyd
home
insul
materi
construct
materi
chipboard
plywood
waterbas
paint
fabric
clean
agent
disinfect
tobacco
smoke
also
make
major
contribut
sourc
includ
heat
cook
air
pollut
constitut
one
greatest
health
threat
vulner
popul
includ
infant
children
major
sourc
pollut
indoor
exposur
environment
tobacco
smoke
et
combust
biomass
fuel
outdoor
exposur
combust
product
traffic
industri
includ
fuel
product
air
pollut
compris
heterogen
mix
ozon
carbon
monoxid
co
nitrogen
dioxid
sulphur
dioxid
polycycl
aromat
hydrocarbon
pah
lead
heavi
metal
fine
particul
matter
less
micron
diamet
pm
less
micron
pm
particul
matter
releas
motor
vehicl
particularli
diesel
engin
consist
organ
substanc
nitrat
sulfat
element
carbon
semiquinon
metal
ozon
gener
ultraviolet
light
interact
nitrogen
oxid
volatil
organ
compound
exposur
pollut
vari
local
season
howev
acceler
industri
develop
nation
urban
center
toxic
level
air
pollut
world
health
organ
estim
million
death
global
death
per
year
due
indoor
outdoor
air
pollut
southeast
asia
western
pacif
greatest
burden
air
pollut
region
greatest
morbid
mortal
associ
air
pollut
air
pollut
exposur
pregnanc
major
impact
fetal
develop
respiratori
health
child
pregnanc
physiolog
chang
increas
respiratori
rate
minut
ventil
increas
fat
accumul
promot
increas
uptak
concentr
pollut
bodi
pregnanc
oxygen
demand
increas
higher
concentr
circul
co
less
oxygen
carri
capac
risk
decreas
oxygen
deliveri
fetu
fetal
hypoxia
blunt
alveolar
develop
promot
primari
pulmonari
hypertens
pollut
cross
placent
barrier
nicotin
other
may
induc
inflamm
alter
growth
factor
pathway
exampl
pm
prenat
exposur
throughout
pregnanc
induc
chang
fetal
cord
blood
biomark
high
fmslike
tyrosin
decreas
placent
growth
factor
consist
antiangiogen
state
possibl
placent
dysfunct
factor
wheez
asthma
offspr
matern
smoke
pregnanc
major
caus
low
birth
weight
prematur
deliveri
factor
predispos
increas
risk
airflow
obstruct
impact
airflow
obstruct
longlast
observ
adulthood
nicotin
cross
placent
barrier
detect
neonat
cord
blood
thu
nicotin
may
neg
affect
lung
develop
evid
matern
smoke
pregnanc
induc
cord
blood
dna
methyl
norwegian
mother
child
cohort
studi
dna
methyl
cpg
affect
ten
gene
import
detoxif
develop
function
includ
ahrr
aryl
hydrocarbon
receptor
repressor
xenobiot
metabol
enzym
growth
factor
independ
transcript
repressor
importantli
dna
methyl
pattern
confirm
separ
valid
studi
support
conserv
epigenet
impact
due
matern
smoke
importantli
addit
effort
encourag
cessat
smoke
may
therapeut
approach
mitig
effect
matern
smoke
offspr
recent
placebo
control
random
doubl
blind
prospect
trial
administ
vitamin
c
smoke
pregnant
women
determin
whether
increas
matern
level
vitamin
c
prevent
airflow
obstruct
offspr
vitamin
c
administr
improv
tidal
lung
function
measur
newborn
infant
compar
control
infant
intervent
current
investig
larger
studi
determin
whether
vitamin
c
longlast
effect
protect
lung
function
offspr
mother
smoke
sever
complex
challeng
need
overcom
make
progress
studi
mechan
prenat
air
pollut
tobacco
smoke
exposur
affect
offspr
first
pregnant
women
may
expos
mixtur
pollut
vari
concentr
time
durat
new
model
incorpor
measur
monitor
devic
satellitederiv
aerosol
optic
depth
spectroradiometri
improv
spatiotempor
accuraci
determin
pollut
exposur
howev
complex
multipl
pollut
still
complic
abil
model
exposur
attribut
outcom
specif
constitu
second
mani
host
factor
includ
socioeconom
statu
matern
stress
matern
genom
microbiom
metabolom
interact
pollut
exposur
togeth
creat
matern
exposom
factor
impact
fetal
develop
final
difficult
separ
antenat
pollut
exposur
exposur
infanc
childhood
determin
rel
impact
lung
diseas
child
alveolar
develop
continu
adolesc
therefor
interact
host
factor
child
exposur
pollut
et
may
continu
impact
lung
develop
risk
asthma
lower
respiratori
tract
infect
howev
potenti
new
lung
parenchym
growth
lung
repair
also
provid
opportun
mitig
earli
injuri
viru
rsv
pathogenesi
controversi
present
discuss
interact
environment
factor
rsv
diseas
defin
immun
mediat
associ
sever
ill
two
independ
popul
infant
rsv
bronchiol
reveal
sever
rsv
infect
determin
genotyp
individu
environment
exposur
lp
rsvinfect
infant
sever
diseas
exhibit
high
ratio
manifest
high
ratio
respiratori
secret
ratio
present
infant
sever
rsv
indic
polar
murin
model
rsv
infect
confirm
lp
exposur
genotyp
polar
influenc
diseas
phenotyp
togeth
result
identifi
environment
genet
factor
influenc
rsv
pathogenesi
reveal
high
ratio
associ
sever
diseas
definit
sever
asthma
compris
three
categori
carri
differ
public
health
messag
challeng
untreat
sever
asthma
difficulttotreat
sever
asthma
treatmentresist
sever
asthma
untreat
sever
asthma
compris
children
area
insuffici
access
asthma
care
discuss
sinc
solut
larg
lie
outsid
hand
pediatrician
note
dramat
benefit
make
simpl
low
cost
treatment
wide
avail
develop
world
need
rememb
vast
major
children
simpl
remedi
properli
use
need
howev
note
studi
low
middl
incom
set
marker
sever
outcom
set
adequ
treatment
avail
convent
sever
therapi
resist
asthma
stra
treatmentresist
sever
asthma
defin
either
need
high
dose
treatment
control
diseas
b
either
uncontrol
symptom
acut
attack
despit
high
dose
treatment
see
tabl
revers
factor
address
defin
level
treatment
children
beclomethason
equival
mcgday
plu
long
act
agonist
leukotrien
receptor
antagonist
least
fail
trial
agent
persist
airflow
limit
fev
zscore
mean
system
steroid
trial
plu
shortact
agonist
level
fev
withhold
short
longact
agonist
howev
although
stra
bad
outcom
uk
nation
review
asthma
death
nrad
around
die
meet
criteria
sever
asthma
despit
death
rather
sever
outcom
http
whyasthmastillkillsfullreportpdf
marker
sever
consid
asthmat
propos
framework
airway
diseas
compris
airway
diseas
extrapulmonari
comorbid
lifestyl
environment
factor
consid
clinic
trait
treatment
especi
treatabl
expect
benefit
treatment
would
also
add
physician
behavior
signific
effect
nrad
sinc
know
children
asthma
readili
treat
low
dose
inhal
corticosteroid
ic
regularli
properli
administ
focu
initi
outsid
airway
rather
uncrit
ad
therapi
subject
comprehens
review
elsewher
abstract
necessarili
select
extrapulmonari
marker
sever
food
allergi
common
anticip
children
ventil
asthma
pediatr
intens
care
unit
picu
though
whether
caus
fellow
travel
unclear
differenti
acut
asthma
acut
anaphylaxi
patholog
may
difficult
sever
atopi
food
allergi
unclear
whether
caus
marker
stra
either
way
children
multipl
aeroallergen
sensit
big
skin
prick
test
wheal
andor
high
specif
ige
high
risk
group
sever
asthma
fungal
sensit
saf
gener
agre
pediatr
definit
pragmat
stra
pattern
sensit
spt
sige
fungu
sinc
allerg
bronchopulmonari
aspergillosi
rare
ever
seen
children
asthma
includ
definit
ige
adult
shown
children
saf
wors
inflamm
given
level
treatment
thu
put
greater
risk
sever
asthma
obes
evid
asthma
complic
obes
patholog
differ
nonobes
asthma
associ
steroid
resist
greater
likelihood
admiss
picu
certainli
obes
potenti
treatabl
trait
b
environmentlifestyl
marker
sever
nonadher
probabl
singl
import
caus
asthma
attack
sever
outcom
manifest
underus
ic
overus
shortact
agonist
saba
saba
overus
readili
identifi
dispens
record
detect
ic
underus
difficult
questionnair
ineffect
hand
prescript
uptak
equat
inhal
electron
monitor
mere
mean
devic
activ
area
smart
technolog
need
also
identifi
nonadher
one
thing
remedi
quit
anoth
pattern
seek
health
care
repeat
attend
emerg
depart
failur
attend
regular
review
anoth
concern
featur
like
marker
chaotic
famili
life
therefor
poor
supervis
treatment
well
environment
exposur
allergen
exposur
sensit
associ
steroid
resist
viral
infect
high
risk
asthma
attack
passiv
smoke
also
associ
steroid
resist
c
physician
behavior
asthma
sever
asthma
plan
failur
plan
deal
attack
anoth
advers
marker
nrad
asthma
plan
shown
effect
care
review
acut
attack
determin
follow
whether
modifi
previou
sever
asthma
attack
root
mainli
lie
outsid
airway
quit
clear
sever
attack
major
risk
factor
anoth
sever
attack
death
asthma
well
long
term
associ
acceler
declin
lung
function
sever
attack
never
event
prompt
detail
reassess
asthma
manag
child
persist
airway
eosinophilia
adult
studi
least
marker
risk
acut
attack
certainli
biolog
plausibl
uncontrol
eosinophil
inflamm
contribut
sever
exacerb
whether
driven
children
dubiou
neither
sarp
abl
demonstr
due
classic
cytokin
two
studi
mean
antityp
monoclon
antibodi
use
uncrit
need
trial
children
extrapol
adult
studi
absenc
airway
eosinophilia
addon
therapi
phenotyp
although
possibl
azithromycin
may
help
absenc
treatment
option
make
vulner
group
studi
need
absenc
intraepitheli
neutrophil
airway
neutrophilia
bal
submucosa
featur
pediatr
stra
recent
shown
presenc
intraepitheli
neutrophil
associ
less
sever
asthma
quit
differ
shown
adult
pediatr
stra
differ
diseas
take
home
messag
import
way
reduc
poor
asthma
control
reduc
asthma
attack
increas
airway
treatment
deploy
latest
monoclon
get
basic
right
includ
adher
environment
exposur
effect
manag
plan
attack
high
risk
patient
sever
attack
overus
saba
underus
ic
alway
best
kiss
keep
simpl
stupid
howev
experienc
patient
pediatrician
never
take
asthma
lightli
still
kill
diseas
allerg
rhiniti
one
common
chronic
diseas
childhood
intern
studi
asthma
allergi
childhood
report
averag
preval
rhiniti
among
children
yearold
children
burden
allerg
rhiniti
individu
patient
societi
often
underestim
gener
lack
data
risk
factor
phenotyp
rhiniti
childhood
adolesc
diagnosi
allerg
rhiniti
base
upon
clinic
histori
includ
type
durat
frequenc
symptom
exacerb
factor
children
teenag
rhiniti
experi
upper
respiratori
symptom
includ
nasal
blockag
itch
wateri
rhinorrhea
sneez
may
present
atyp
cough
snore
worth
note
despit
often
troublesom
symptom
rhiniti
often
ignor
minor
symptomat
children
appropri
diagnosi
manag
plan
examin
nose
essenti
diagnosi
rhiniti
alway
carri
atop
sensit
ascertain
use
skin
prick
test
measur
allergenspecif
serum
ige
howev
test
posit
absenc
symptom
posit
skin
test
ige
confirm
express
rhiniti
symptom
upon
allergen
exposur
allergendriven
rhiniti
symptom
seen
associ
allergen
exposur
data
demonstr
quantif
atop
sensit
use
titer
sige
antibodi
size
skin
prick
test
wheal
increas
specif
test
relat
presenc
sever
rhiniti
investig
may
requir
evalu
possibl
diagnos
eg
measur
nasal
mucociliari
clearanc
nasal
nitric
oxid
nasal
endoscopi
acoust
rhinometri
etc
manag
strategi
allerg
rhiniti
includ
avoid
relev
allergen
possibl
oral
intranas
antihistamin
intranas
corticosteroid
firstlin
treatment
allerg
rhiniti
intranas
corticosteroid
greatest
efficaci
addon
treatment
may
includ
oral
leukotrien
receptor
antagonist
intranas
cromoglyc
patient
allerg
rhiniti
age
five
year
inadequ
control
use
standard
pharmacolog
treatment
allergenspecif
immunotherapi
help
consid
amongst
schoolag
children
allerg
rhiniti
frequent
coexist
asthma
often
preced
asthma
develop
mount
bodi
evid
patient
asthma
rhiniti
sever
lower
respiratori
symptom
compar
asthma
alon
exampl
amongst
adult
patient
asthma
comorbid
rhinosinus
consider
poorer
qualiti
life
chronic
rhiniti
import
comorbid
sever
asthma
similarli
children
asthma
allerg
rhiniti
advers
impact
asthma
control
addit
children
adolesc
moderatesever
asthma
treat
inhal
corticosteroid
concurr
allerg
increas
use
emerg
care
servic
compar
patient
without
rhiniti
among
children
asthma
recruit
hospit
asthma
clinic
presenc
allerg
rhiniti
shown
signific
advers
effect
asthma
control
even
asthma
consid
adequ
control
populationbas
studi
demonstr
amongst
children
asthma
presenc
rhiniti
signific
advers
effect
asthma
sever
among
asthmat
children
rhiniti
frequent
wheez
attack
increas
risk
sever
attack
wheez
associ
speech
limit
increas
risk
frequent
visit
famili
doctor
increas
risk
greater
school
absente
asthma
increas
risk
treatment
allerg
rhiniti
improv
asthma
control
studi
netherland
treatment
allerg
rhiniti
intranas
corticosteroid
reduc
advers
effect
rhiniti
asthma
sever
control
similarli
studi
describ
adjust
use
antihistamin
chang
associ
rhiniti
asthma
sever
adjust
use
intranas
corticosteroid
result
small
consist
reduct
risk
observ
consist
find
retrospect
cohort
older
children
adult
show
among
patient
asthma
rhiniti
treat
allerg
rhiniti
significantli
less
like
visit
emerg
depart
hospit
treat
result
studi
suggest
prove
amongst
children
asthma
rhiniti
appropri
treatment
rhiniti
intranas
corticosteroid
may
improv
asthma
control
definit
answer
obtain
appropri
design
random
control
trial
howev
yet
longterm
trial
children
howev
note
studi
among
cipp
xvi
abstract
children
mildmoder
asthma
intermitt
allerg
rhiniti
shown
intranas
corticosteroid
may
improv
exerciseinduc
bronchospasm
contrast
doubleblind
random
crossov
trial
amongst
adult
asthma
persist
allerg
rhiniti
demonstr
steroid
spare
effect
ad
intranas
corticosteroid
low
dose
inhal
corticosteroid
lower
airway
outcom
recent
metaanalysi
studi
assess
effect
intranas
corticosteroid
asthma
outcom
patient
allerg
comorbid
asthma
conclud
intranas
corticosteroid
may
improv
lower
airway
outcom
studi
need
confirm
role
intranas
corticosteroid
spray
therapi
asthma
outcom
conclus
allerg
rhiniti
common
import
comorbid
childhood
asthma
children
asthma
assess
presenc
rhiniti
appropri
treat
allevi
upper
lower
respiratori
symptom
asthma
frequent
diagnos
chronic
condit
childhood
global
estim
million
peopl
asthma
given
frequenc
asthma
diagnosi
made
face
would
appear
diagnos
asthma
easi
howev
asthma
diagnos
made
basi
symptom
report
littl
object
evid
support
diagnosi
asthma
lead
diagnosi
asthma
delay
definit
diagnosi
condit
children
treatment
start
mani
littl
object
evid
whilst
symptom
report
clearli
start
point
suggest
possibl
asthma
symptom
insuffici
confirm
diagnosi
symptom
non
specif
cough
featur
normal
childhood
viral
infect
parentreport
wheez
could
mean
respiratori
nois
upper
lower
airway
cultur
even
word
wheez
yet
great
weight
put
item
clinic
practic
epidemiolog
studi
singl
gold
standard
test
asthma
posit
neg
predict
valu
test
far
optim
howev
say
test
undertaken
rather
test
carri
suggest
histori
logic
fashion
demonstr
one
key
featur
character
asthma
chronic
inflammatori
diseas
variabl
airflow
obstruct
airway
hyperrespons
object
test
includ
measur
peak
flow
peak
flow
variabl
spirometri
demonstr
revers
airflow
obstruct
exhal
nitric
oxid
feno
induc
sputum
test
airway
hyperrespons
methacholin
histamin
challeng
test
may
avail
specialist
center
howev
abil
measur
peak
flow
assess
variabl
across
period
record
respons
short
act
beta
agonist
saba
avail
level
care
measur
feno
like
becom
increasingli
avail
absenc
variabl
airflow
obstruct
inflamm
realli
call
question
diagnosi
trial
treatment
may
help
case
provid
clearli
document
evid
respons
deterior
stop
cipp
xvi
abstract
retrospect
review
dutch
children
diagnos
asthma
diagnosi
confirm
diagnosi
confirm
presenc
document
recurr
wheez
dyspnea
demonstr
revers
airflow
obstruct
spirometri
need
addit
test
histamin
challeng
twentythre
percent
probabl
asthma
confirmatori
test
deem
overdiagnos
remaind
never
diagnos
asthma
prescrib
inhal
anoth
unknown
reason
canadian
studi
recruit
children
diagnosi
asthma
control
carri
object
test
diagnosi
asthma
confirm
clinician
assess
plu
either
revers
bronchoconstrict
posit
methacholin
challeng
fortyf
percent
case
overdiagnos
symptomat
control
underdiagnos
howev
emphas
studi
crosssect
previous
state
singl
gold
standard
test
asthma
may
diagnosi
correct
made
child
grown
symptom
given
variabl
asthma
assess
singl
day
unlik
suffici
exclud
diagnosi
context
suggest
symptom
nonetheless
studi
highlight
infrequ
object
test
carri
import
review
diagnosi
misdiagnosi
asthma
potenti
caus
harm
children
may
prescrib
unnecessari
potenti
harm
medic
altern
diagnosi
dose
inhal
corticosteroid
ic
may
relentlessli
increas
view
lack
symptomat
respons
howev
note
mani
children
diagnos
asthma
dutch
canadian
studi
either
low
dose
ic
need
saba
impli
fact
children
symptom
receiv
diagnosi
asthma
rel
trivial
symptom
almost
half
children
diagnos
asthma
fact
healthi
children
reinforc
view
asthma
mild
diseas
highlight
nation
review
asthma
death
potenti
advers
outcom
includ
death
poorli
recogn
among
health
care
profess
complac
put
genuin
poorli
control
diseas
risk
correct
diagnosi
cornerston
good
asthma
manag
effort
made
ensur
diagnosi
underpin
object
test
led
specul
wheez
ill
earli
childhood
may
repres
common
diseas
process
exist
sever
discret
wheez
phenotyp
underpin
differ
biolog
process
endotyp
greater
understand
phenotyp
heterogen
abil
discrimin
discret
phenotyp
earli
life
either
clinicopatholog
featur
biolog
marker
underli
process
could
advanc
opportun
stratifi
intervent
alter
natur
histori
asthma
wheez
across
life
cours
one
longest
run
populationbas
studi
asthma
outcom
world
start
melbourn
report
follow
age
year
particip
recruit
childhood
age
year
recruit
children
classifi
categori
mild
wheezi
bronchiti
moder
wheezi
bronchiti
asthma
sever
asthma
success
follow
survey
sever
asthma
childhood
associ
greatest
risk
persist
frequent
asthma
adulthood
furthermor
sever
asthma
associ
lower
lung
function
fev
fvc
establish
childhood
despit
acceler
rate
declin
adulthood
group
much
greater
risk
copd
midadult
life
subject
histori
asthma
wheez
similar
find
lung
function
deficit
exist
midchildhood
persist
adulthood
observ
dunedin
studi
associ
wheez
persist
throughout
transit
tucson
children
respiratori
studi
semin
show
earli
childhood
phenotyp
base
tempor
pattern
wheez
relat
asthma
lung
function
outcom
later
life
prospect
follow
birth
cohort
show
earli
onset
wheez
becam
asymptomat
midchildhood
progress
asthma
associ
low
lung
function
soon
birth
subsequ
follow
up
birth
cohort
tucson
cipp
xvi
abstract
group
also
show
transient
earli
wheez
phenotyp
associ
persist
low
lung
function
adolesc
earli
adulthood
develop
tucson
paradigm
use
datadriven
approach
analyz
parent
report
wheez
ill
age
year
larg
birth
cohort
uk
confirm
associ
transient
earli
wheez
low
lung
function
midchildhood
identifi
three
phenotyp
wheez
persist
midchildhood
character
age
onset
sinc
replic
sever
time
independ
cohort
evid
extern
valid
comparison
phenotyp
base
clinic
observ
emerg
work
wheez
began
earli
within
first
month
birth
persist
midchildhood
strongest
associ
clinic
report
asthma
low
lung
function
compar
nonwheez
transient
phenotyp
insight
gain
analysi
manchest
asthma
allergi
studi
maa
link
individu
health
record
show
persist
wheez
phenotyp
could
stratifi
without
frequent
health
care
util
essenti
sever
form
persist
wheez
term
persist
troublesom
wheez
interestingli
genet
studi
suggest
subphenotyp
persist
wheez
persist
troublesom
wheez
distinct
associ
genet
loci
share
phenotyp
recent
follow
earli
childhood
phenotyp
adolesc
confirm
earlyonset
persist
wheez
associ
asthma
low
lung
function
bronchodil
respons
increas
feno
adolesc
phenotyp
also
strongli
associ
allerg
sensit
midchildhood
cohort
maa
studi
longitudin
assess
sensit
model
atop
statu
indic
strongest
associ
hospit
wheezeasthma
poorer
lung
function
higher
airway
reactiv
pool
resourc
combin
data
expertis
appli
sophist
statist
approach
data
interrog
enabl
us
reach
posit
target
phenotyp
intervent
almost
certainli
associ
earli
onset
troublesom
wheez
associ
evid
multipl
atop
sensit
juri
still
whether
phenotyp
identifi
latent
class
analysi
cluster
approach
repres
discret
biolog
entiti
differ
manifest
fundament
process
next
challeng
extend
analys
includ
triangul
detail
clinic
biomark
inform
fulli
understand
endotyp
associ
persist
allerg
asthma
target
intervent
pathway
prevent
modifi
long
term
morbid
condit
hospitalizationsyear
asthma
approxim
death
day
diseas
one
countri
highest
preval
sever
asthma
world
major
challeng
manag
sever
asthma
children
countri
usual
correct
diagnosi
clinic
present
welltrain
profession
avail
referr
tertiari
center
difficulti
access
control
medic
higher
cost
mani
children
sever
asthma
difficulttotreat
problemat
asthma
percentag
children
resist
convent
pharmacolog
therapi
high
dose
corticosteroid
longact
leukotrien
receptor
antagonist
repres
one
greatest
challeng
clinic
manag
asthma
type
sever
asthma
classifi
sever
therapyresist
asthma
stra
strongli
associ
atop
phenotyp
children
import
emphas
mani
patient
problemat
asthma
present
stra
often
anoth
diseas
inadequ
inhal
techniqu
adherencetotreat
problem
relev
environment
factor
comorbid
allerg
rhiniti
obes
sever
gastroesophag
reflux
among
other
lmic
popul
present
diseas
still
deserv
greater
understand
dissemin
moreov
child
uncontrol
asthma
use
highdos
inhal
corticosteroid
longact
agonist
laba
antileukotrien
deserv
care
evalu
clinic
followup
least
month
specialist
area
adequ
diagnosi
manag
henc
due
complex
correct
diagnosi
problemat
asthma
children
welltrain
profession
multidisciplinari
team
essenti
major
constraint
lmic
set
regard
pharmacolog
treatment
children
stra
step
gina
guidelin
indic
also
relat
higher
cost
difficulttoaccess
treatment
lmic
anti
ige
omalizumab
omalizumab
shown
signific
clinic
benefit
mani
children
stra
howev
high
cost
limit
countri
lowercost
option
group
children
would
use
daili
system
corticosteroid
children
respond
treatment
use
associ
seriou
advers
event
conclus
burden
sever
asthma
children
high
larg
social
impact
lmic
review
guidelin
closer
look
discuss
effect
way
manag
sever
asthma
set
limit
econom
resourc
essenti
reduc
burden
diseas
children
asthma
lmic
asthma
one
common
chronic
disord
childhood
mani
epidemiolog
studi
confirm
increas
trend
asthma
parallel
econom
develop
urban
research
around
world
tri
determin
factor
might
respons
induc
trend
wellknown
factor
associ
asthma
atopi
air
pollut
exposur
tobacco
smoke
urban
dietari
chang
consumpt
fruit
veget
infect
includ
viral
bacteri
caus
person
factor
low
birth
weight
born
caesarean
section
determin
exact
mechan
factor
may
respons
asthma
difficult
task
one
thing
clear
one
two
factor
respons
increas
trend
asthma
western
world
studi
china
reveal
interest
find
may
help
us
understand
asthma
western
world
past
two
decad
extrem
rapid
econom
develop
unpreced
china
histori
parallel
rapid
increas
preval
childhood
asthma
document
data
guangzhou
standard
methodolog
although
sensit
factor
associ
asthma
high
rate
sensit
document
mani
year
rise
asthma
preval
level
air
pollut
high
mani
chines
citi
yet
preval
cipp
xvi
abstract
asthma
highli
pollut
citi
chongq
rel
low
perhap
strike
contrast
differ
asthma
allergi
urban
rural
environ
similar
rural
protect
asthma
found
western
countri
exposur
farm
anim
cow
consumpt
unpasteur
farm
milk
major
factor
rural
china
dairi
cow
consumpt
farm
milk
extrem
rare
last
studi
children
southern
china
exposur
domest
poultri
signific
factor
explain
rural
protect
furthermor
gene
express
studi
suggest
mark
upregul
variou
immun
regulatori
gene
rural
popul
environment
exposur
may
respons
differ
result
rural
protect
asthma
allergi
dr
louis
fleme
nation
heart
lung
institut
royal
brompton
hospit
london
uk
email
lfleme
imperialacuk
asthma
common
chronic
diseas
children
global
world
children
like
asthma
symptom
past
year
countri
develop
world
among
highest
preval
report
asthma
although
death
rate
highest
low
middl
incom
countri
death
rate
remain
high
develop
countri
exceed
mani
low
incom
countri
therefor
greater
avail
resourc
financi
term
access
effect
asthma
medic
reflect
asthma
outcom
three
key
area
act
barrier
effect
asthma
treatment
develop
countri
diagnosi
asthma
children
base
symptom
report
rather
object
test
like
account
high
preval
seen
countri
lead
complac
appear
asthma
common
trivial
diseas
ineffect
risk
stratif
mean
appropri
resourc
direct
need
recent
year
larg
increas
number
gener
inhal
corticosteroid
ic
icslong
act
beta
agonist
laba
combin
inhal
devic
avail
prescrib
multipl
differ
devic
switch
devic
noth
improv
inhal
techniqu
good
evid
coordin
nation
plan
asthma
involv
level
care
includ
commun
pharmaci
school
primari
secondari
tertiari
care
lead
improv
asthma
outcom
cost
save
howev
wide
replic
develop
countri
patchi
provis
specialist
care
poorli
defin
care
pathway
lack
effect
educ
patient
carer
includ
health
care
profession
despit
legisl
aim
ensur
new
drug
test
appropri
children
pipelin
develop
new
drug
remain
particularli
slow
children
therapeut
target
novel
biolog
identifi
studi
adult
asthma
may
less
relev
pediatr
diseas
rel
small
number
children
usual
adolesc
recruit
phase
trial
result
children
rare
analyz
publish
separ
licens
novel
drug
children
often
lag
behind
adult
licens
restrict
access
drug
may
benefit
note
access
effect
treatment
healthcar
develop
countri
part
compar
low
middl
incom
countri
howev
differenti
avail
resourc
alway
reflect
outcom
need
done
ensur
resourc
squander
asthma
care
deliv
effect
ultralaba
prolong
durat
action
allow
oncedaili
dose
like
due
retent
within
cell
membran
persist
presenc
drug
near
adrenoreceptor
ar
use
asthma
limit
combin
therapi
ic
given
wellknown
possibl
safeti
issu
monotherapi
indic
vilanterol
highli
select
partial
agonist
compound
current
molecul
approv
use
asthma
adolesc
combin
fluticason
furoat
ffvi
efficaci
safeti
demonstr
clinic
trial
includ
adolesc
adult
asthmat
patient
ic
ad
inhal
vi
well
compar
ffvi
placebo
current
use
ic
icslaba
activ
compar
adolesc
age
year
age
compris
asthma
popul
ffvi
clinic
develop
program
approv
age
rang
grant
european
medicin
agenc
ema
base
data
contrari
food
drug
administr
fda
consid
adequ
riskbenefit
shown
data
earli
phase
trial
children
age
year
fail
show
signific
improv
lung
function
despit
good
toler
ffvi
combin
current
option
gina
step
onward
adolesc
countri
regulatori
approv
ff
cover
lowand
highdos
ic
categori
put
benefit
regard
treatment
adher
oncedaili
dose
although
recent
cochran
review
highlight
low
moder
qualiti
evid
ffvi
asthma
conclus
drawn
pediatr
popul
due
scarc
data
current
avail
studi
ultralaba
ongo
pediatr
clinic
develop
plan
asthma
data
earli
phase
trial
nearli
full
agonist
indacaterol
combin
mometason
avail
includ
adolesc
least
one
larg
trial
ongo
regulatori
submiss
other
focus
children
year
plan
data
pediatr
patient
avail
yet
offici
plan
olodaterol
abediterol
whose
product
develop
plan
combin
therapi
asthma
uncertain
preliminari
respect
whether
ultralaba
prone
safeti
issu
due
loss
bronchoprotect
effect
function
desensit
mechan
yet
uncertain
rais
parasympathet
tone
provid
rational
use
antimuscarin
agent
asthma
tiotropium
administ
mist
inhal
subject
larg
clinic
develop
program
includ
children
adolesc
age
year
adult
evid
synthesi
shown
addit
tiotropium
ic
laba
reduc
exacerb
use
replac
laba
lead
heterogen
result
differ
outcom
result
pediatr
trial
present
publish
throughout
earli
lead
recent
fda
approv
children
year
older
ema
approv
children
still
pend
result
suggest
children
adolesc
moder
andor
sever
asthma
use
tiotropium
addon
ic
without
mainten
therapi
gener
welltoler
safe
lung
function
paramet
gener
improv
reflect
efficaci
bronchodil
trial
primari
endpoint
achiev
across
age
rang
asthma
sever
observ
improv
measur
asthma
control
statist
signific
place
tiotropium
manag
pediatr
asthma
thu
still
unclear
gina
guidelin
suggest
use
addon
therapi
adult
adolesc
patient
step
histori
exacerb
data
need
directli
compar
efficaci
tiotropium
versu
laba
identifi
predictor
eg
fix
airway
obstruct
clarifi
benefit
outcom
exacerb
establish
longterm
effect
airway
model
use
lama
adult
asthma
cipp
xvi
abstract
subject
earli
phase
trial
data
avail
yet
children
adolesc
fixeddos
combin
therapi
may
provid
synergi
drug
compon
well
enhanc
complianc
asid
previous
mention
combin
treatment
sever
doubl
laba
lama
tripl
icslabalama
combin
therapi
current
clinic
develop
also
grow
interest
develop
drug
two
differ
primari
pharmacolog
action
molecul
bifunct
drug
effort
obtain
efficaci
corticosteroid
fewer
advers
effect
focu
ligand
glucocorticoid
receptor
preferenti
induc
transrepress
littl
transactiv
activ
segra
dissoci
steroid
sever
compound
enter
clinic
develop
new
addit
therapeut
toolbox
greatli
welcom
mani
challeng
lie
ahead
drug
becom
valid
option
current
manag
pediatr
asthma
compani
develop
plan
pediatr
age
rang
plan
may
encount
trial
recruit
extrapol
issu
result
expect
within
decad
aspect
patient
caretak
prefer
type
devic
reallif
experi
implement
new
intervent
children
exist
treatment
must
consid
avail
drugdevic
combin
may
vari
around
world
due
regulatori
econom
motiv
need
solid
evid
efficaci
safeti
medicin
base
patientrelev
endpoint
across
differ
age
evalu
whether
ad
therapeut
valu
current
exist
option
includ
exist
soon
avail
biolog
would
allow
clarifi
role
current
stepwis
futur
phenotypeori
treatment
approach
asthma
heterogen
diseas
airway
character
revers
airflow
obstruct
bronchial
hyperrespons
airway
inflamm
major
patient
current
treatment
base
inhal
glucocorticoid
ic
bronchodil
leukotrien
pathway
inhibitor
offer
good
control
diseas
howev
true
refractori
patient
popul
increas
risk
morbid
mortal
make
greater
asthma
econom
cost
base
cluster
analys
molecular
phenotyp
biomark
differenti
respons
therapi
last
decad
increas
appreci
heterogen
asthma
inde
substanti
divers
clinic
inflammatori
featur
diseas
sever
studi
identifi
cluster
patient
featur
correspond
earlyonset
atopicallerg
asthma
late
onset
atop
nonatop
asthma
exercis
induc
asthma
paucigranulocyt
asthma
asthma
associ
obes
etc
variou
phenotyp
character
differ
type
degre
inflammatori
immun
respons
approach
also
led
recognit
potenti
distinct
endotyp
type
helper
lymphocyteassoci
earli
onset
allerg
endotyp
late
onset
endotyp
interleukin
il
associ
eosinophil
endotyp
mast
cell
associ
exerciseinduc
endotyp
late
onset
obes
endotyp
neutrophil
andor
noninflammatori
noncorticosteroid
respons
endotyp
although
endotyp
character
asthmat
patient
area
activ
research
date
specif
pathway
target
biolog
agent
identifi
also
term
biolog
biolog
therapeut
synthes
live
organ
direct
specif
determin
cipp
xvi
abstract
treatment
allerg
diseas
exampl
includ
agent
target
immunoglobulin
ig
e
b
lymphocyt
c
cytokin
proinflammatori
cytokin
tumor
necrosi
factor
tnf
e
chemokin
receptor
f
lymphocyt
surfac
adhes
molecul
almost
biolog
current
avail
test
use
asthmat
patient
target
compon
like
asthma
endotyp
pathway
character
eosinophil
inflamm
driven
lymphocyt
respons
variou
agent
allergen
parasit
virus
produc
caus
shift
cell
differenti
cell
stimul
ige
product
blymphocyt
upon
antigen
bind
ige
activ
mast
cell
eosinophil
releas
toxic
granul
cytokin
regul
eosinophil
matur
recruit
activ
act
local
chemoattract
eosinophil
mast
cell
whilst
induc
ige
synthesi
releas
mucu
product
epitheli
cell
favor
goblet
cell
metaplasia
eosinophil
inflamm
relat
allergi
sinc
patient
sever
asthma
eosinophil
inflamm
show
atop
sensit
normal
serum
ige
includ
antiig
receptor
human
monoclon
antibodi
hmab
antiig
first
cytokin
blocker
omalizumab
antiig
recombin
hmab
regist
treatment
patient
sever
persist
allerg
asthma
import
find
cochran
review
omalizumab
reduc
steroid
use
exacerb
improv
asthma
control
questionnair
acq
score
healthrel
qualiti
life
score
treatment
efficaci
patient
howev
seem
relat
presenc
eosinophil
airway
inflamm
serum
ige
level
basophil
eosinophil
express
receptor
first
random
control
trial
patient
asthma
show
antagonist
mepolizumab
reduc
blood
eosinophil
count
prevent
blood
eosinophilia
latephas
respons
follow
allergen
challeng
effect
late
asthmat
respons
bronchial
hyperreact
howev
subsequ
trial
patient
eosinophil
asthma
demonstr
mepolizumab
treatment
reduc
asthma
attack
find
confirm
subsequ
studi
also
show
signific
oral
corticosteroid
spare
effect
trial
lebrikizumab
patient
moderatetosever
asthma
show
improv
particularli
high
serum
periostin
concentr
high
feno
strong
trend
reduc
exacerb
thu
block
receptor
subunit
affect
signal
trial
receptora
antagonist
dupilumab
subgroup
patient
persist
moderatetosever
asthma
blood
eosinophilia
show
signific
fewer
exacerb
withdrawn
long
act
b
adrenoceptor
agonist
inhal
corticosteroid
treatment
addit
forc
expiratori
volum
second
fev
improv
significantli
acq
score
also
drop
treatment
group
also
show
reduct
fraction
exhal
nitric
oxid
feno
ige
thymu
activationregul
chemokin
tarc
level
preliminari
data
asthma
endotyp
hope
provid
benefici
effect
longterm
lowdos
azithromycin
patient
noneosinophil
asthma
preliminari
data
efficaci
navarixin
sch
receptorb
antagonist
whilst
posit
effect
report
treatment
brodalumab
hmab
moderatetosever
asthmat
result
studi
show
like
disord
possibl
success
introduc
biolog
treatment
asthma
larg
depend
possibl
identifi
specif
patient
subgroup
select
measur
biomark
directli
influenc
treatment
pediatr
pulmonari
hypertens
ph
rare
devast
diseas
may
present
pediatr
age
group
ph
pathophysiolog
disord
associ
multipl
clinic
condit
complic
major
cardiovascular
respiratori
diseas
associ
consider
morbid
mortal
pediatr
patient
preval
caus
ph
congenit
heart
diseas
idiopath
pulmonari
arteri
hyper
normal
pulmonari
vascular
bed
essenti
normal
lung
structur
metabol
ga
exchang
toler
exercis
workload
perinat
factor
may
contribut
increas
risk
late
develop
ph
adulthood
adult
ph
pediatr
ph
differ
vascular
function
structur
genet
natur
histori
respons
right
ventricl
increas
load
ph
specif
therapi
ph
defin
mean
pulmonari
arteri
pressur
mmhg
rest
month
age
measur
cardiac
catheter
nice
classif
categor
pulmonari
hypertens
ph
pulmonari
arteri
hypertens
ph
due
left
heart
diseas
ph
due
lung
diseas
andor
hypoxia
chronic
thromboembol
ph
ph
due
unclear
multifactori
mechan
pulmonari
arteri
hypertens
pah
describ
group
patient
ph
precapillari
ph
normal
pulmonari
arteri
wedg
pressur
mmhg
pulmonari
vascular
resist
index
wood
unit
wu
pulmonari
vascular
research
institut
introduc
term
pediatr
pulmonari
hypertens
vascular
diseas
pphvd
approach
distinguish
ph
without
pulmonari
vascular
diseas
pvd
singl
biventricular
circul
patient
congenit
heart
diseas
chd
singl
ventricl
physiolog
often
meet
criteria
defin
may
benefit
similar
pharmacolog
strategi
patient
fontantyp
hemodynam
pulmonari
vascular
resist
pvr
index
wu
transpulmonari
gradient
mm
hg
suggest
definit
pphvd
children
suspect
confirm
ph
refer
specialist
ph
pediatr
center
central
care
concentr
expertis
benefici
manag
patient
detail
medic
histori
care
physic
examin
essenti
diagnost
criteria
hemodynam
cardiac
pulmonari
arteri
catheter
gold
standard
establish
diagnosi
inde
method
direct
accur
measur
pulmonari
arteri
pressur
complement
acut
vasodil
test
inhal
nitric
endothelin
mediat
two
receptor
type
b
blockad
mechan
etra
bosentan
oral
dual
etra
approv
pediatr
use
caus
pap
pvr
decreas
improv
exercis
capac
seriou
side
effect
includ
liver
enzym
elev
anemia
impair
fertil
teratogen
regular
liver
function
test
recommend
children
receiv
bosentan
ambrisentan
oral
et
areceptor
antagonist
daili
formul
repercuss
liver
enzym
macitentan
novel
dual
etra
also
show
sign
hepat
toxic
fewer
drug
interact
bosentan
phase
iii
trial
pediatr
patient
current
ongo
sildenafil
current
approv
pediatr
use
act
prevent
breakdown
smooth
muscl
cell
cyclic
guanosin
monophosph
improv
pulmonari
vasodil
show
antiprolif
effect
oral
sildenafil
use
cautious
pediatr
popul
care
dose
accord
weight
frequent
assess
due
report
increas
mortal
patient
use
higher
dose
side
effect
includ
headach
flush
noseble
hypotens
tadalafil
longer
durat
action
use
pediatr
popul
studi
prostacyclin
act
increas
pulmonari
vasodil
inhibit
vascular
remodel
analog
includ
epoprostenol
treprostinil
iloprost
selexipag
first
two
deliv
continu
intraven
infus
treatment
choic
sever
pulmonari
hypertens
rv
failur
epoprostenol
given
central
venou
line
place
patient
risk
advers
event
due
short
halflif
risk
rebound
ph
case
interrupt
administr
advers
side
effect
includ
bradycardia
hypotens
thrombocytopenia
dosedepend
treprostinil
longer
halflif
enabl
subcutan
infus
mini
pump
iloprost
administ
nebul
caus
acut
bronchospasm
patient
selexipag
oral
select
prostacyclin
receptor
agonist
promis
new
therapi
favor
side
effect
profil
show
signific
reduct
pvr
adult
treatment
pediatr
pulmonari
hypertens
aim
improv
surviv
qualiti
life
exercis
capac
hemodynam
reduc
overal
risk
improv
clinic
echocardiograph
hemodynam
risk
factor
goal
met
monotherapi
combin
therapi
use
combin
therapi
may
efficaci
address
multipl
pathophysiolog
pathway
simultan
whether
kind
strategi
initi
earli
use
two
drug
sequenti
ad
second
drug
previou
one
still
studi
high
risk
patient
inhal
intraven
prostacyclin
consid
deterior
occur
despit
maxim
therapi
techniqu
atrial
septostomi
pulmonarytosystem
shunt
appli
lung
heartlung
transplant
last
therapeut
resort
figur
cardiac
highpressur
highflow
lesion
like
ventricular
septal
defect
lead
ph
children
cyanot
congenit
heart
diseas
pulmonari
highflow
highpressur
defect
highest
risk
patient
consid
oper
undergo
surgeri
earli
stage
follow
target
therapi
need
older
patient
increas
risk
develop
sever
form
ph
even
surviv
surgeri
suggest
surgeri
may
worsen
prognosi
character
sudden
increas
pap
pvr
pulmonari
hypertens
crisi
carri
high
risk
prevent
involv
maintain
adequ
oxygen
satur
acid
base
homeostasi
sedat
need
avoid
agit
inhal
nitric
oxid
standard
therapi
improv
pulmonari
vasodil
rv
function
cardiac
output
increas
pvr
caus
vasoconstrict
decreas
vascular
growth
pulmonari
vascular
remodel
left
ventricular
dysfunct
treatment
involv
low
ventil
volum
permiss
hypercapnia
highfrequ
oscillatori
ventil
need
inhal
nitric
oxid
last
resort
extracorpor
membran
oxygen
surgic
repair
mandatori
gener
clinic
stabil
regular
echocardiographi
recommend
pulmonari
hypertens
may
persist
cardiac
catheter
eventu
consid
sensibl
subtl
vascular
abnorm
chronic
diffus
lung
diseas
like
bronchopulmonari
dysplasia
lead
ph
echocardiographi
recommend
evalu
patient
hypoxemia
avoid
pediatr
patient
reveal
registri
show
estim
surviv
rate
time
diagnosi
respect
report
also
shown
improv
surviv
rate
pediatr
pah
patient
pah
repair
chd
address
care
may
present
unfavor
outcom
adult
classic
eisenmeng
hemodynam
better
surviv
patient
idiopath
pulmonari
arteri
hypertens
children
pahchd
ipah
similar
mortal
surviv
report
respect
paul
aurora
cardiovascular
pulmonari
system
close
relat
health
diseas
mean
system
need
consid
evalu
symptom
cough
breathless
cardiac
diseas
affect
pulmonari
function
lung
diseas
affect
cardiac
function
addit
primari
ciliari
dyskinesia
caus
simultan
cardiac
pulmonari
diseas
propos
summar
understand
differ
area
mani
children
present
respiratori
symptom
also
evalu
congenit
heart
diseas
chd
cardiac
diseas
summari
stridor
may
result
extrins
compress
airway
commonli
great
vessel
pulmonari
arteri
sling
dilat
left
atrium
ventricl
cipp
xvi
abstract
wheez
andor
cough
may
consequ
pulmonari
edema
reduc
exercis
toler
andor
hypoxia
result
cardiac
lesion
pulmonari
hypertens
mani
cardiac
condit
difficult
diagnos
histori
examin
target
investig
may
requir
particular
atrial
septal
defect
idiopath
pulmonari
arteri
hypertens
may
present
nonspecif
symptom
high
index
suspicion
requir
occur
due
abnorm
vessel
anatomi
increas
blood
flow
pulmonari
system
due
left
right
shunt
combin
two
fail
heart
cardiac
dilat
lead
pulmonari
edema
result
larg
left
right
shunt
also
condit
obstruct
pulmonari
venou
return
therefor
increas
pulmonari
venou
pressur
turn
increas
pressur
pulmonari
capillari
imbal
hydrostat
pressur
dictat
flow
water
across
alveolar
capillari
membran
result
accumul
water
pulmonari
interstitium
alveoli
physiolog
result
reduc
lung
complianc
impair
oxygen
transport
pulmonari
capillari
system
mani
children
patholog
also
engorg
peribronchi
vessel
show
bronchial
cuf
lung
imag
caus
compress
small
airway
socal
cardiac
asthma
diuret
provid
effect
palliat
definit
therapi
possibl
condit
produc
right
left
shunt
eg
arterioven
malform
tetralog
fallot
result
poor
ventilationperfus
match
total
volum
blood
pass
pulmonari
circul
reduc
pass
directli
caval
system
system
arteri
system
child
therefor
display
hypoxemia
either
without
mild
hypercarbia
fontan
procedur
commonest
situat
right
ventricl
bypass
absent
venou
blood
caval
system
directli
connect
pulmonari
arteri
case
volum
blood
pass
pulmonari
circul
normal
child
low
pressur
pulmonari
circul
depend
low
resist
mani
children
anatomi
develop
collater
system
venou
system
manag
condit
challeng
mucolyt
agent
provid
littl
benefit
cardiac
transplant
immedi
cur
pulmonari
arteri
hypertens
pah
defin
pulmonari
arteri
pressur
mmhg
rest
primari
term
idiopath
pulmonari
arteri
hypertens
ipah
secondari
cardiac
diseas
pulmonari
diseas
medic
manag
ipah
chang
dramat
last
decad
multipl
agent
avail
palli
relief
unfortun
disadvantag
none
cur
subject
eventu
proceed
lung
transplant
pah
secondari
cardiac
diseas
common
seen
adult
chd
patient
research
focus
sever
end
spectrum
also
known
eisenmeng
syndrom
pulmonari
arteri
pressur
suprasystem
lead
right
left
shunt
across
cardiac
commun
subsequ
hypoxemia
recent
attent
address
earlier
stage
diseas
particularli
investig
subject
prone
develop
secondari
pah
other
also
note
subject
respond
well
pah
therapi
trial
differ
combin
consid
increasingli
recogn
primari
ciliari
dyskinesia
pcd
result
situ
inversu
also
complex
organ
later
defect
includ
chd
child
may
born
cardiac
isomer
dextrocardia
also
varieti
septal
defect
outflow
tract
abnorm
assum
embryon
nodal
cilia
base
embryon
node
play
role
establish
correct
organ
later
develop
embryo
genet
analysi
aspect
pcd
phenotyp
challeng
given
larg
number
gene
involv
howev
establish
genet
mutat
encod
outer
dynein
arm
inner
dynein
arm
protein
associ
chd
human
contrast
associ
found
mutat
encod
central
apparatu
radial
cipp
xvi
abstract
spike
protein
clinician
first
challeng
diagnosi
pulmonologist
care
child
pcd
must
low
threshold
detail
cardiac
evalu
cardiologist
care
child
known
chd
must
low
threshold
ciliari
studi
diagnosi
establish
treatment
chd
complet
standard
appropri
caution
children
bronchiectasi
abnorm
circul
cerebrospin
fluid
children
sever
ventricular
dysfunct
result
chd
cardiac
transplant
may
therapeut
option
long
term
surviv
follow
cardiac
transplant
children
excel
specif
challeng
children
chd
case
pulmonologist
may
ask
give
physiolog
heart
lung
close
intertwin
oblig
physician
alert
pulmonari
cardiac
diagnos
child
breathless
also
requir
pulmonologist
good
understand
impact
cardiac
diseas
upon
lung
upon
pulmonari
circul
close
commun
pulmonologist
cardiologist
essenti
comprehens
discuss
topic
lung
bleed
beyond
scope
present
previou
meet
cipp
updat
topic
offer
risk
repetit
updat
talk
present
focu
specif
clinic
etiolog
better
understand
natur
histori
idiopath
pulmonari
hemosiderosi
iph
use
flexibl
bronchoscopi
tool
improv
diagnosi
activ
intervent
pulmonari
bleed
hemosiderosi
patholog
find
specif
diseas
etiolog
process
character
find
hemosiderinladen
macrophag
hlm
alveolar
space
condit
may
variou
underli
primari
secondari
caus
lung
bleed
rare
infanc
childhood
incid
vari
site
report
case
per
million
report
sweden
case
per
million
report
japan
low
incid
also
underli
pauciti
systemat
inform
causal
bleed
review
larg
referr
center
children
young
adult
report
cystic
fibrosi
cf
repres
congenit
heart
diseas
remain
infect
cf
neoplasm
caus
typic
classifi
idiopath
clinic
case
exemplifi
defin
caus
lung
bleed
discuss
present
includ
bleed
relat
cardiac
defect
case
cor
triatriatum
metabol
disord
exemplifi
lanehamilton
syndrom
hemosiderosi
associ
celiac
diseas
pulmonaryren
syndrom
exemplifi
granulomatosi
polyangi
formerli
wegen
granulomatosi
definit
diagnosi
bleed
lung
nonhemoptys
patient
challeng
eventu
reli
bronchoscopi
detail
physic
examin
nonspecif
rang
subtl
tachypnea
dyspnea
variabl
crackl
wheez
pulmonari
hypertens
frank
respiratori
failur
fever
chest
discomfort
pain
infrequ
observ
laboratori
work
beyond
anemia
suggest
nonspecif
radiograph
chang
nonspecif
rang
minim
infiltr
massiv
parenchym
involv
featur
separ
hemorrhag
process
infiltr
fleet
natur
howev
patient
small
frequent
episod
bleed
radiograph
may
reflect
chronic
diffus
interstiti
involv
chang
minim
acut
recurr
ct
scan
suggest
also
specif
mri
cite
offer
specif
presenc
blood
decreas
signal
imag
rare
recogn
radiologist
pulmonari
function
test
infrequ
avail
age
rang
discuss
nonspecif
howev
diffus
studi
dl
co
may
result
unexpectedli
high
rapid
uptak
tracer
ga
hemoglobin
alveolar
space
center
diseas
control
cdc
classifi
aiph
nosolog
entiti
clinic
confirm
case
ill
previous
healthi
infant
age
year
gestat
age
inde
initi
associ
cleveland
seri
made
stachybotri
chartarum
atra
mold
may
found
waterdamag
home
ultim
associ
substanti
similarli
boston
seri
caus
assum
relat
underli
suscept
bleed
von
willebrand
diseas
vwd
ultim
propos
infant
underli
vulner
deem
underpin
bleed
would
precipit
injuri
lung
common
environment
caus
possibl
viral
infect
howev
sinc
direct
trigger
could
unifi
case
identifi
final
etiolog
identifi
public
emerg
seri
success
control
recalcitr
pulmonari
bleed
procedur
undertaken
intervent
last
resort
case
hemorrhag
visual
procedur
resolut
follow
treatment
immedi
unequivoc
definit
editori
follow
case
report
heslet
emphas
intervent
airsid
alveolu
constitut
key
advantag
direct
instil
advoc
earli
liber
use
intervent
dah
consid
remark
eas
efficaci
appar
absent
side
effect
prognosi
limit
inform
longterm
outcom
pulmonari
hemosiderosi
older
studi
suggest
overal
prognosi
may
favor
idiopath
case
howev
recent
larg
multicent
french
studi
promis
speci
diversif
ntm
within
cf
popul
appear
vari
geograph
distribut
unit
state
mycobacterium
avium
complex
mac
slow
grow
ntm
frequent
recogn
pulmonari
pathogen
europ
countri
howev
mycobacterium
abscessu
appear
major
pathogen
cf
relationship
ntm
infect
aspergillu
infect
without
abpa
found
might
associ
specif
immun
dysregul
involv
subgroup
cf
patient
addit
corticosteroid
itraconazol
treatment
also
found
associ
increas
incid
ntm
cf
treatment
ntm
pulmonari
diseas
least
month
involv
multipl
antibiot
patient
ntm
isol
may
meet
at
criteria
diseas
requir
close
monitor
clinic
statu
serial
ct
scan
sputumbronchoalveolar
lavag
surveil
research
requir
improv
identif
ntm
cf
respiratori
sampl
understand
pathophysiolog
ntm
infect
within
cf
lung
develop
effect
drug
regimen
ntmcf
pulmonari
diseas
protract
bacteri
bronchiti
pbb
defin
condit
isol
wet
cough
last
four
week
evid
specif
caus
cough
resolv
fulli
prolong
antibiot
treatment
consid
rather
benign
condit
properli
treat
may
advanc
chronic
suppur
lung
diseas
csld
bronchiectasi
affect
mainli
younger
children
half
patient
age
year
one
third
year
old
older
year
lead
pathogen
involv
pbb
nontyp
haemophilu
influenza
approx
follow
streptococcu
pneumonia
moraxella
catarrhali
approx
combin
pathogen
occur
infect
pseudomona
aeruginosa
resist
pathogen
occur
simpl
pbb
found
child
chronic
cough
search
underli
etiolog
undertaken
eg
cystic
fibrosi
primari
ciliari
dyskinesia
immunodefici
main
risk
factor
protract
bacteri
bronchiti
reduc
mucociliari
clearanc
viral
respiratori
infect
lack
reconvalesc
viral
bronchiti
may
lead
impair
airway
clearanc
secondari
ciliari
dyskinesia
persist
bronchial
inflamm
facilit
secondari
bacteri
infect
airway
stabil
disord
tracheobronchomalacia
detect
children
pbb
often
gener
popul
one
studi
evalu
children
pbb
age
month
author
found
laryngomalacia
tracheomalacia
anoth
studi
found
tracheomalacia
young
children
pbb
far
malacia
caus
factor
extent
instabl
airway
may
secondari
prolong
infect
protract
cough
remain
studi
immunodefici
disord
humor
immun
associ
insuffici
protect
may
facilit
bacteri
growth
airway
local
heat
use
wood
coal
describ
signific
risk
factor
pediatr
airway
industri
pollut
industri
pollut
shown
risk
factor
respiratori
infect
children
import
part
industri
emiss
small
particl
particul
matter
pm
whose
concentr
may
rise
local
advers
climat
condit
correl
pm
exposur
increas
respiratori
symptom
repeatedli
document
pathogenesi
pbb
usual
develop
consequ
insult
impair
airway
defens
risk
factor
may
start
gradual
base
continu
damag
mucosa
eg
recurr
aspir
environment
trigger
ger
appar
initi
acut
event
high
enzymat
activ
neutrophil
enhanc
process
studi
fraction
neutrophil
bal
high
bacteri
infect
retent
mucu
high
proteolyt
activ
neutrophil
lead
csld
damag
bronchial
wall
gradual
develop
bronchiectasi
diagnos
earli
process
interrupt
antibiot
treatment
even
develop
mild
bronchiectasi
revers
pathogen
interfer
defens
mechan
form
biofilm
cleav
immunoglobulin
main
symptom
bacteri
bronchiti
wet
cough
without
sputum
product
wet
sound
cough
suggest
intrabronchi
secret
variou
qualiti
consist
abil
produc
sputum
age
train
depend
infant
young
children
abl
spit
sputum
howev
success
train
physiotherapist
earli
third
year
life
cough
usual
present
day
night
often
pronounc
morn
secret
accumul
overnight
cough
may
worsen
physic
exercis
occasion
patient
may
wheez
base
obstruct
mucu
transient
variabl
chang
cough
recurr
wheez
may
signal
bronchial
hyperrespons
rais
suspicion
asthma
pbb
fever
gener
absent
infect
limit
bronchial
tree
lead
system
inflammatori
respons
fever
elev
acut
phase
protein
associ
acut
exacerb
sever
affect
lung
parenchyma
pneumonia
children
protract
wet
cough
diagnos
earli
gener
practic
gener
practition
detect
analyz
symptom
differenti
blood
count
crp
erythrocyt
sediment
rate
belong
standard
firstlin
investig
gp
also
trace
possibl
environment
risk
smoke
local
heat
local
risk
household
detail
investig
import
mainli
children
recurr
pbb
chest
xray
sweat
test
assess
clinic
risk
primari
ciliari
dyskinesia
help
exclud
sever
underli
condit
cooper
children
pulmonari
function
test
flowvolum
loop
done
revers
test
use
inhal
rapid
act
agonist
child
abl
produc
sputum
sampl
sent
cultur
microscop
evalu
antibiot
would
administ
treat
child
stop
antibiot
least
hour
may
increas
yield
analysi
nonexpector
child
deep
suction
hypopharynx
morn
physiotherapi
may
help
effect
method
microbiolog
sampl
bronchoscopi
indic
children
singl
episod
pbb
even
children
recurr
pbb
usual
necessari
expector
suffici
howev
bronchoscopi
may
exclud
underli
patholog
flexibl
bronchoscopi
perform
spontan
breath
allow
visual
assess
airway
anatomi
exclud
aspir
foreign
bodi
also
help
assess
mucos
inflamm
observ
stabil
airway
breath
cough
perform
bronchial
toilett
remov
mucu
plug
directli
sampl
mucu
addit
standard
bronchoalveolar
lavag
perform
specimen
sent
microbiolog
differenti
cytolog
stain
lipidladen
macrophag
anaerob
mycot
cultur
also
consid
addit
examin
must
includ
detail
ent
assess
exclud
focal
infect
upper
airway
area
adenoid
sinus
immunolog
test
mainli
check
humor
immun
includ
concentr
vaccin
specif
antibodi
total
serum
ige
allerg
sensit
test
context
symptom
histori
develop
bronchiectasi
suspect
diagnost
method
choic
high
resolut
computer
tomographi
hrct
uncompl
pbb
easili
treat
howev
untreat
persist
bacteri
infect
accompani
inflamm
associ
risk
develop
csld
bronchiectasi
antibiot
treatment
base
expect
confirm
microbi
etiolog
mostli
broad
spectrum
antibiot
target
hemophillu
spp
pneumococcu
moraxella
use
product
penicillinas
respect
select
antibiot
uncompl
pbb
resolv
two
week
cours
appropri
antibiot
also
shown
random
control
trial
analyz
twoweek
cours
amoxycillinclavulan
placebo
children
activ
arm
show
significantli
higher
resolut
rate
children
placebo
arm
good
effect
antibiot
confirm
also
systemat
review
even
though
consist
data
effect
physiotherapi
pbb
use
use
least
basic
techniqu
airway
clearanc
techniqu
especi
young
children
even
though
antibiot
usual
effect
relaps
occur
case
good
effect
repeat
antibiot
cours
child
high
frequenc
recurr
prolong
cours
antibiot
may
consid
underli
condit
found
critic
treat
patholog
togeth
treatment
bronchiti
protract
bacteri
bronchiti
condit
suspect
children
protract
wet
cough
quick
diagnosi
earli
initi
proper
treatment
lead
complet
resolut
prevent
sever
sequela
chronic
suppur
lung
diseas
bronchiectasi
pneumococc
isol
suscept
penicillin
thirdgener
cephalosporin
well
describ
vitro
rate
report
worldwid
surveil
signific
geograph
variat
high
rate
spain
franc
part
southeast
asia
usa
furthermor
macrolid
resist
also
problem
commun
main
mechan
resist
via
alter
penicillinbind
protein
overcom
achiev
adequ
local
drug
level
ie
decreas
sensit
rather
absolut
resist
yet
evid
clinic
treatment
failur
infect
outsid
central
nervou
system
use
high
bronchiol
first
common
acut
lower
respiratori
tract
viral
infect
infant
less
month
age
lead
caus
hospit
age
group
although
children
mild
symptom
infant
month
old
hospit
diagnosi
bronchiol
usa
account
hospit
annual
extrem
elev
hospit
charg
care
relat
disord
addit
hospit
infant
requir
admiss
intens
care
unit
impair
gener
condit
recurr
apnea
episod
respiratori
failur
requir
mechan
ventil
bronchiol
also
associ
disproportion
number
death
among
children
younger
year
age
resourcelimit
nation
number
much
lower
industri
countri
death
bronchiol
show
incid
nine
time
higher
influenza
viru
infect
larg
epidemiolog
studi
also
demonstr
clear
relationship
bronchiol
earli
infanc
subsequ
bronchial
hyperreact
childhood
adulthood
viral
also
host
factor
establish
magnitud
cipp
xvi
abstract
structur
function
damag
respiratori
structur
ultim
extent
sever
durat
first
infect
later
consequ
pathogen
frequent
caus
bronchiol
infant
respiratori
syncyti
viru
rsv
follow
human
rhinoviru
hrv
respiratori
virus
metapneumoviru
mpv
human
bocaviru
hbov
enteroviru
ev
adenoviru
adv
influenza
viru
iv
human
coronaviru
hcov
parainfluenza
viru
piv
also
implic
bacteri
coinfect
rare
describ
infant
bronchiol
except
hrv
infect
peak
spring
fall
epidemiolog
report
shown
gener
season
bronchiol
epidem
peak
decemb
march
everi
year
differ
clinic
present
bronchiol
due
variou
virus
report
exampl
shown
hrvassoci
bronchiol
may
result
shorter
hospit
length
bronchiol
attribut
rsv
consist
rsv
infect
seem
caus
sever
diseas
addit
one
constant
characterist
infant
hospit
rsvinduc
bronchiol
tendenc
younger
hospit
virus
final
although
differ
respons
medic
intervent
identifi
consist
suggest
infant
hospit
hrv
rsv
may
distinct
respons
antiinflammatori
therapi
treatment
system
corticosteroid
seem
like
reduc
recurr
wheez
infant
rv
bronchiol
oppos
rsv
bronchiol
differ
probabl
reflect
involv
differ
pathogenet
mechan
number
hostrel
risk
factor
sever
rsv
bronchiol
identifi
varieti
epidemiolog
studi
immatur
innat
acquir
immun
respons
incomplet
develop
respiratori
system
surpris
risk
factor
includ
prematur
low
birth
weight
young
chronolog
age
environment
factor
also
rais
risk
hospit
admiss
rate
number
sibl
live
perman
child
household
day
care
attend
tobacco
smoke
exposur
hostrel
risk
factor
male
gender
presenc
chronic
pulmonari
diseas
infanc
congenit
heart
diseas
structur
function
airway
abnorm
neuromuscular
syndrom
immunodefici
cystic
fibrosi
syndrom
howev
epidemiolog
data
show
vast
major
infant
hospit
condit
belong
risk
group
suggest
viral
host
factor
includ
classic
risk
factor
may
account
diseas
sever
play
put
role
magnitud
subsequ
respiratori
morbid
rsvmediat
infect
induc
sever
respiratori
symptom
almost
exclus
young
children
immunedefici
immunedepress
patient
infant
bronchiol
symptom
sever
enough
warrant
hospit
increas
risk
develop
recurr
wheez
asthma
childhood
also
adult
life
mechan
explain
higher
incid
wheez
sever
bronchiol
unclear
sinc
known
whether
viral
bronchiol
simpli
identifi
infant
increas
risk
subsequ
wheez
inform
come
rsv
hrv
infect
besid
direct
cytopath
effect
local
host
inflammatori
respons
rsv
play
primari
role
develop
sign
symptom
character
diseas
combin
effect
viru
inflammatori
respons
lead
epitheli
damag
slough
epithelium
mucu
product
ultim
airway
obstruct
inde
infant
sever
diseas
cytopath
effect
induc
rsv
amplifi
presenc
potent
inflammatori
reaction
mediat
activ
polymorphonuclear
leukocyt
natur
killer
cell
first
innat
respons
associ
defect
host
adapt
immun
respons
character
reaction
lead
ineffici
ginterferonmedi
stimul
cytotox
tcell
ineffect
clear
viru
poorli
stimul
macrophag
phagocyt
activ
endors
dead
cell
clearanc
persist
airway
hyperreact
earlylif
rsv
infect
may
relat
least
part
abnorm
neural
control
airway
smooth
muscl
tone
induc
rsv
upregul
nerv
growth
factor
ngf
trka
neurokinin
nk
receptor
function
promot
acetylcholin
releas
signal
molecul
induc
product
neurokinin
substanc
p
mediat
involv
pathogenesi
neurogen
inflamm
bronchomotor
tone
disregul
addit
persist
latent
viral
infect
site
bone
marrow
cell
could
maintain
constant
stimul
immun
system
explain
respiratori
sequela
rsvinduc
bronchiol
contrast
rsv
hrv
affect
peopl
age
induc
minim
airway
cell
cytotox
hrvinduc
cytopath
effect
airway
structur
inflammatori
cell
associ
inflammatori
reaction
releas
mediat
lead
predispos
individu
recurr
persist
bronchial
hyperreact
current
hypothesi
hrv
infect
may
favor
allerg
sensit
bia
characterist
immun
respons
allergen
atop
individu
may
modifi
host
antimicrobi
defens
thu
attenu
abil
fight
viral
infect
via
immun
deviat
addit
releas
cytokin
chemokin
could
result
amplif
inflammatori
respons
infect
present
cold
asthma
exacerb
compar
children
rsv
infect
hrv
infect
present
often
atop
dermat
blood
eosinophilia
acut
viral
infect
causal
role
allerg
sensit
favor
sever
hrvinduc
ill
support
demonstr
allerg
sensit
may
preced
hrvassoci
wheez
may
lead
increas
risk
wheez
ill
caus
hrv
rsv
thu
rsv
seem
act
induc
subsequ
airway
hyperreact
first
infect
character
extens
airway
damag
induct
neurogen
inflamm
latter
possibl
respons
longlast
bronchial
hyperreact
contrast
hrv
seem
act
trigger
induc
extens
releas
proinflammatori
mediat
cipp
xvi
abstract
lead
recurr
persist
bronchial
hyperreact
allerg
patient
individu
predispos
atop
sensit
prevent
bronchiol
includ
environment
prophylaxi
decreas
transmiss
respiratori
infect
b
pharmacolog
prophylaxi
specif
rsv
bronchiol
administr
human
monoclon
antibodi
palivizumab
epidem
season
particular
risk
categori
despit
decad
research
licens
rsv
vaccin
effect
therapeut
agent
market
current
larg
number
candid
evalu
preclin
phase
undergo
clinic
trial
still
controversi
regard
best
therapeut
approach
bronchiol
support
treatment
approach
recommend
recent
intern
guidelin
reli
mainli
oxygen
therapi
hydrat
develop
nextgener
tool
manag
rsv
infect
recent
larg
focus
three
major
target
area
viral
entri
machineri
viral
rnadepend
rnapolymeras
complex
viral
compon
assembl
mani
rsv
inhibitor
describ
recent
year
none
complet
phase
clinic
trial
year
worldwid
due
rsv
diseas
addit
rsv
causal
link
recurr
wheez
associ
pediatr
asthma
ciliari
dyskinesia
chronic
lung
diseas
although
primari
ciliari
dyskinesia
consid
rare
lung
diseas
preval
children
chronic
respiratori
infect
estim
high
extrapulmonari
manifest
includ
leftright
later
defect
often
situ
inversu
totali
occur
nearli
patient
primari
ciliari
dyskinesia
respiratori
ciliari
dysfunct
also
found
patient
heterotaxi
congenit
heart
defect
demonstr
import
cilia
function
normal
cardiac
develop
male
infertil
common
due
impair
sperm
motil
ultrastructur
defect
ciliat
cell
line
fallopian
tube
led
specul
subfertil
ectop
pregnanc
occur
women
associ
conclus
establish
histor
diagnosi
primari
ciliari
dyskinesia
base
compat
clinic
phenotyp
specif
ultrastructur
defect
ciliari
axonem
unfortun
ultrastructur
examin
cilia
diagnost
test
primari
ciliari
dyskinesia
signific
drawback
ciliari
defect
acquir
nonspecif
chang
may
seen
relat
exposur
environment
pollut
infect
normal
ciliari
ultrastructur
exclud
primari
ciliari
dyskinesia
found
approxim
affect
individu
newer
test
measur
ciliari
beat
pattern
use
highspe
videomicroscopi
nasal
nitric
oxid
measur
increasingli
use
diagnost
screen
tool
immunofluoresc
stain
ciliari
protein
anoth
approach
hold
promis
may
address
limit
transmiss
electron
microscopi
genet
test
becom
power
diagnost
tool
primari
ciliari
dyskinesia
collabor
intern
research
effort
gene
link
diseas
patient
test
biallel
mutat
gene
gene
discoveri
continu
percentag
rise
mani
mutat
gene
link
specif
ultrastructur
defect
ciliari
dysmotil
includ
gene
encod
compon
outer
dynein
arm
inner
dynein
arm
dynein
regulatori
complex
nexin
radial
spoke
central
apparatu
recent
mutat
gene
code
sever
cytoplasm
protein
found
appear
import
role
cilia
assembl
protein
transport
genet
provid
unexpect
insight
phenotyp
primari
ciliari
dyskinesia
instanc
biallel
mutat
dynein
axonem
heavi
chain
gene
encod
outer
dynein
arm
protein
clearli
lead
diseas
associ
ultrastructur
defect
cilia
normal
rapid
beat
multicili
differenti
dna
synthesi
associ
cell
cycl
protein
mcida
found
symptom
consist
primari
ciliari
dyskinesia
rare
cilia
epitheli
surfac
mutat
protein
nexindynein
regulatori
complex
act
ruler
determin
precis
repetit
structur
protein
along
axonem
yield
inconsist
ultrastructur
abnorm
character
absent
inner
dynein
arm
axonem
misplac
radial
spoke
microtubular
disorgan
cilia
crosssect
studi
show
children
microtubular
disorgan
primarili
due
biallel
mutat
sever
lung
diseas
contrast
individu
biallel
mutat
milder
respiratori
phenotyp
contrast
motor
cilia
primari
sensori
cilia
solitari
immotil
organel
locat
surfac
nondivid
cell
origin
consid
vestigi
remnant
structur
bronchiectasi
preval
difficult
ascertain
develop
countri
children
hospit
pneumonia
suspect
develop
bronchiectasi
overcrowd
poor
hous
smoke
exposur
cigarett
cook
fire
also
increas
risk
combin
poor
access
healthcar
underdiagnosi
bronchiectasi
like
high
preval
certainli
probabl
common
enough
lose
orphan
diseas
statu
differ
associ
report
studi
across
countri
eg
nearli
secondari
tb
china
mostli
postinfecti
india
associ
high
rate
hiv
south
africa
access
investig
also
issu
present
children
bronchiectasi
commonli
present
chronic
wet
cough
recurr
respiratori
infect
wheez
asthma
report
persist
chest
xray
abnorm
follow
respiratori
infect
particularli
focal
chang
anoth
common
pathway
earli
pneumonia
key
risk
factor
symptomsxray
chang
persist
twothird
high
risk
children
one
year
singl
admiss
twoyearsag
diagnosi
often
signific
delay
onset
symptom
definit
diagnosi
current
diagnost
guidelin
suggest
referr
week
wet
cough
episod
product
wet
cough
per
year
howev
differ
studi
children
mean
two
hospit
admiss
four
infect
first
year
life
mean
two
year
chronic
cough
mean
five
chest
xray
rang
chest
ct
scan
request
suggest
commun
health
practition
awar
bronchiectasi
still
low
signific
barrier
earli
diagnosi
exist
particularli
ct
scan
access
due
economicgeograph
constraint
concern
regard
radiat
dose
gener
anesthet
treatment
commenc
base
suspici
histori
delay
obtain
definit
diagnosi
prognosi
children
long
term
outcom
seem
depend
sever
diagnosi
subsequ
rate
exacerb
howev
unlik
adult
diseas
improv
even
revers
associ
pediatr
bronchiectasi
earli
referr
diagnosi
essenti
essenti
littl
evid
manag
new
drug
use
better
alreadi
develop
pediatr
databas
sever
score
would
help
evolut
familyl
organ
websit
would
power
step
forward
probabl
signific
burden
diseas
exit
develop
world
lack
access
diagnost
facil
avail
therapi
major
concern
registri
person
bronchiectasi
embarc
europ
wwwbronchiectasiseu
bronchoconstrict
peripher
blood
eosinophilia
howev
later
abpa
cf
consensu
criteria
state
serum
ige
iuml
consid
diagnost
cf
lung
abpa
caus
acut
deterior
pulmonari
function
suspicion
rais
clinic
respons
convent
antibiot
therapi
symptom
may
includ
increas
wheez
fever
malais
thick
sputum
brown
cipp
xvi
abstract
black
bronchial
cast
high
level
clinic
suspicion
necessari
earli
recognit
specif
treatment
abpa
immedi
start
order
prevent
lung
damag
corticosteroid
effect
drug
treat
abpa
dose
schedul
durat
therapi
remain
poorli
defin
patient
cf
abpa
often
requir
prolong
therapi
oral
corticosteroid
associ
sever
side
effect
monthli
puls
highdos
iv
methylprednisolon
therapi
mgkg
day
consecut
day
shown
effect
treatment
cf
patient
abpa
induc
significantli
less
side
effect
compar
convent
oral
therapi
furthermor
patient
treat
puls
iv
methylprednisolon
seem
respond
faster
therapi
antifung
oral
treatment
eg
itraconazol
voriconazol
propos
adjunct
therapi
patient
steroiddepend
abpa
steroidrel
advers
effect
exact
role
antifung
agent
treatment
abpa
still
debat
decreas
fungal
load
antifung
agent
help
control
antigen
stimulu
thu
diminish
inflammatori
respons
howev
definit
evid
exist
regard
efficaci
patient
cf
abpa
omalizumab
monoclon
antibodi
ige
also
tri
manag
abpa
signific
clinic
improv
reduct
hospit
exacerb
patient
concomit
cf
abpa
demonstr
could
benefici
steroid
spare
therapi
patient
howev
data
requir
clarifi
role
omalizumab
expens
therapi
recommend
treatment
approach
chronic
lung
diseas
asthma
copd
affect
million
peopl
major
caus
prematur
death
children
adult
worldwid
gener
accept
mani
chronic
lung
diseas
result
complex
genet
environment
interact
therefor
increas
attent
given
mani
environment
lifestyl
factor
air
pollut
smoke
physic
activ
diet
research
show
earli
nutrit
play
critic
role
healthi
lung
develop
underpin
increas
propens
mani
respiratori
noncommunic
diseas
diet
may
import
modifi
risk
factor
develop
progress
manag
chronic
lung
diseas
children
adult
eg
bronchopulmonari
dysplasia
bpd
asthma
cystic
fibrosi
cf
copd
undernutrit
overnutrit
may
signific
effect
pulmonari
function
poor
growth
risk
chronic
lung
diseas
earli
life
malnutrit
relat
impair
immun
result
frequent
sever
respiratori
infect
addit
nutrit
deplet
common
problem
patient
sever
chronic
lung
diseas
bpd
cf
other
hypermetabol
malabsorpt
deplet
fat
free
mass
associ
increas
morbid
signific
impair
health
statu
obes
also
relat
poor
lung
function
increas
preval
asthma
asthma
sever
addit
sever
nutrit
defici
rare
occur
isol
dietari
intervent
potenti
role
reduc
acut
respiratori
ill
relat
morbid
mortal
especi
develop
countri
chronic
lung
diseas
nutrit
intervent
proven
cipp
xvi
abstract
effect
prevent
improv
outcom
evid
scarc
other
pregnant
women
henc
babi
children
year
age
particularli
vulner
micronutri
defici
increas
suscept
acut
chronic
lung
diseas
childhood
addit
multipl
micronutri
defici
coexist
individu
vitamin
defici
relat
impair
immun
function
cell
differenti
zinc
defici
associ
higher
incid
acut
respiratori
infect
major
caus
death
children
year
develop
countri
instead
nutrit
intervent
diet
rich
fruit
veget
seem
protect
recent
metaanalysi
effect
childhood
nutrient
intak
risk
develop
wheez
asthma
show
evid
protect
effect
vitamin
e
zinc
fruit
veget
mediterranean
diet
develop
asthma
also
saadeh
et
al
show
fruit
green
veget
intak
associ
low
preval
wheez
asthma
school
children
age
year
old
adequ
dietari
vitamin
c
intak
also
relat
reduc
wheez
observ
studi
children
asthma
systemat
review
note
higher
matern
intak
vitamin
vitamin
e
zinc
associ
lower
odd
wheez
childhood
relat
dietari
pattern
mediterranean
diet
high
intak
minim
process
plant
food
low
intak
dairi
food
fish
poultri
minim
intak
red
meat
found
protect
effect
allerg
respiratori
diseas
sever
epidemiolog
studi
contrari
western
dietari
pattern
character
high
consumpt
refin
grain
cure
red
meat
dessert
sweet
french
fri
highfat
dairi
product
associ
obes
increas
risk
asthma
children
observ
studi
vitamin
children
asthma
shown
strong
relationship
low
level
vitamin
lower
lung
function
increas
corticosteroid
use
asthma
exacerb
overnutrit
result
obes
clearli
link
respiratori
diseas
particularli
asthma
obes
children
asthma
low
energi
intak
increas
energi
util
compar
term
infant
result
neg
energi
balanc
lead
malnutrit
follow
discharg
infant
bpd
high
risk
persist
growth
failur
possibl
explan
includ
increas
energi
expenditur
poor
oral
feed
skill
toler
concomit
dysfunct
organ
recurr
infect
hospit
therefor
adequ
nutrit
intervent
essenti
match
increas
energi
requir
infant
risk
bpd
although
consensu
regard
optim
nutrit
manag
bpd
mani
suggest
specif
nutrient
supplement
eg
glutamin
selenium
lcpufa
cystein
larginin
lcitrullin
inositol
vitamin
e
c
other
prevent
treat
bpd
theoret
nutrient
may
curb
hyperoxiainduc
injuri
improv
alveolar
develop
howev
evid
supplement
still
controversi
effect
bpd
need
studi
current
evid
show
supplement
vitamin
lcpufa
effect
prevent
bpd
intim
close
relationship
nutrit
statu
respiratori
diseas
infant
preschool
cf
prioriti
improv
longterm
outcom
poor
nutrit
lead
poor
lung
function
increas
number
infect
poor
lung
function
also
caus
increas
energi
util
growth
failur
end
unsatisfactori
outcom
cf
patient
pancreat
insuffici
approxim
one
third
patient
percentil
weight
age
sever
studi
shown
malnutrit
earli
life
relat
impart
lung
function
childhood
micronutri
defici
also
occur
cf
patient
pancreat
insuffici
secondari
malabsorpt
vitamin
e
defici
well
zinc
magnesium
may
present
either
intak
nutrient
absorpt
inadequ
defici
may
also
increas
suscept
respiratori
infect
malnutrit
normal
growth
patient
cf
associ
improv
pulmonari
function
surviv
yen
et
al
show
better
nutrit
statu
age
year
children
cystic
fibrosi
associ
better
lung
function
fewer
complic
greater
surviv
oral
supplement
use
conflict
evid
therefor
consid
nutrit
behavior
approach
gastrostomi
tube
feed
shown
improv
weight
studi
pulmonari
function
also
poor
adher
pancreat
enzym
relat
difficulti
correct
malabsorpt
henc
worst
nutrit
outcom
great
major
ptb
occur
poor
region
world
subsaharan
africa
south
asia
current
infant
born
weight
g
surviv
close
born
week
gestat
age
tertiari
center
surviv
year
age
cohort
main
featur
chronic
lung
diseas
mean
babi
surviv
neonat
period
present
later
morbid
mortal
due
sequela
prematur
bronchopulmonari
dysplasia
bpd
anoth
seri
preterm
infant
born
less
week
gestat
age
show
hospit
first
two
year
life
seri
interven
variabl
play
affect
immatur
pulmonari
system
preterm
newborn
babi
influenc
normal
develop
respiratori
tract
consequ
process
alveolar
growth
format
adequ
pulmonari
microvasculatur
risk
respiratori
morbid
invers
associ
birth
weight
depend
gestat
age
birth
long
list
pulmonari
find
children
born
preterm
includ
increas
incid
pneumonia
bronchiol
frequent
rehospit
respiratori
diseas
chronic
recurr
cough
wheez
bronchial
hyperreact
pulmonari
function
abnorm
chang
present
first
month
year
life
children
born
less
week
gestat
signific
burden
respiratori
diseas
midchildhood
structur
abnorm
lung
function
lower
children
born
preterm
associ
increas
structur
lung
damag
recent
metaanalysi
million
children
worldwid
analyz
chanc
wheez
first
year
life
preterm
birth
found
independ
associ
variabl
higher
risk
popul
lmic
benefit
greatli
new
approach
sinc
burden
diseas
commun
seem
even
greater
observ
affluent
societi
howev
sever
diagnost
advanc
occur
last
year
improv
microbiolog
confirm
support
strategi
promot
better
specimen
collect
includ
induc
sputum
realiz
repeat
specimen
need
children
cipp
xvi
abstract
better
rapid
molecular
diagnost
test
particularli
gene
xpert
xpert
mtbrif
enabl
rapid
diagnosi
simultan
detect
resist
rifampicin
singl
induc
sputum
provid
similar
cultur
yield
gastric
lavag
sequenti
second
specimen
increas
yield
cultur
approxim
primari
care
set
sputum
induct
also
effect
increas
diagnost
yield
ptb
metaanalysi
report
pool
sensit
specif
xpert
mtbrif
singl
respect
compar
cultur
children
ptb
perform
xpert
gastric
lavag
similar
xpert
test
repeat
specimen
provid
higher
yield
specimen
detect
approxim
children
cultur
confirm
diseas
almost
fold
smear
xpert
attract
test
perform
specimen
less
invas
collect
south
african
studi
report
xpert
sequenti
npa
use
microbiolog
confirm
hospit
children
provid
similar
sensit
repeat
xpert
test
howev
npa
provid
lower
yield
specimen
cultur
xpert
stool
specimen
may
offer
promis
strategi
particularli
hivinfect
children
studi
need
xpert
mtbrif
ultra
ultra
detect
diseas
fewer
bacilli
xpert
may
offer
improv
rapid
diagnost
childhood
ptb
paucibacillari
studi
children
underway
diagnost
test
includ
urin
lipoarabinomannan
lam
host
genom
express
profil
improv
immunolog
assay
lam
low
sensit
specif
children
includ
hivinfect
children
make
unsuit
diagnosi
host
genom
signatur
associ
tb
children
identifi
niv
indic
disord
caus
disequilibrium
respiratori
balanc
compris
load
impos
respiratori
system
capac
respiratori
muscl
central
drive
healthi
subject
respiratori
load
ie
effort
subject
perform
gener
breath
low
capac
respiratori
muscl
normal
central
drive
appropri
command
respiratori
muscl
disord
character
increas
respiratori
load
weak
respiratori
muscl
central
drive
increas
demand
respiratori
muscl
howev
imbal
exce
certain
threshold
hypoventil
defin
hypercapnia
hypoxemia
occur
sever
upper
airway
obstruct
airway
malacia
cystic
fibrosi
bronchopulmonari
dysplasia
bronchiol
obliteran
may
respons
excess
respiratori
load
neuromuscular
diseas
involv
motor
neuron
peripher
nerv
neuromuscular
junction
muscl
may
caus
excess
respiratori
muscl
weak
disord
central
drive
rare
may
congenit
ondin
curs
congenit
central
hypoventil
syndrom
acquir
due
compress
injuri
brainstem
disord
involv
impair
two
compon
achondroplasia
mucopolysaccharidos
may
caus
upper
airway
obstruct
brain
stem
compress
choic
type
niv
depend
pathophysiolog
respiratori
failur
cpap
simplest
type
noninvas
respiratori
support
indic
case
isol
obstruct
upper
lower
airway
bipap
indic
two
compon
respiratori
balanc
impair
ie
central
drive
andor
respiratori
muscl
lung
diseas
associ
increas
respiratori
load
aim
niv
unload
respiratori
muscl
patient
normal
central
nervou
system
preserv
respiratori
muscl
capac
ventilatori
assist
preserv
patient
breath
pattern
allow
patient
trigger
assist
breath
appropri
comfort
convers
patient
weak
respiratori
muscl
role
bipap
replac
respiratori
muscl
deliv
posit
pressur
inspir
control
mode
backup
rate
ie
minim
number
breath
deliv
per
minut
ventil
close
normal
respiratori
rate
sleep
age
thu
recommend
cpap
thu
clearli
treatment
sleepdisord
breath
patient
neuromuscular
diseas
final
case
abnorm
central
drive
ventil
abl
take
command
respiratori
muscl
mean
control
mode
valid
criteria
start
long
term
niv
children
clinic
practic
niv
may
initi
acut
set
niv
wean
failur
pediatr
intens
care
unit
picu
abnorm
nocturn
ga
exchang
alon
associ
high
apneahypopnea
index
ahi
polysomnographi
main
challeng
difficulti
niv
initi
children
time
type
investig
polysomnographi
polygraphi
overnight
ga
exchang
record
perform
niv
initi
valu
threshold
paramet
retain
niv
initi
oxygen
andor
carbon
dioxid
level
andor
ahi
assumpt
correct
associ
benefit
niv
difficulti
due
lack
marker
endorgan
morbid
associ
sleepdisord
breath
chronic
respiratori
failur
children
neurocognit
dysfunct
behavior
disturb
common
sever
consequ
obstruct
sleep
apnea
osa
children
deleteri
effect
highli
variabl
one
child
anoth
sleep
studi
part
routin
evalu
child
osa
polysomnographi
repres
gold
standard
polygraphi
continu
monitor
nocturn
ga
exchang
may
use
altern
full
polysomnographi
avail
usual
indic
cpap
residu
osa
adenotonsillectomi
defin
ahi
eventsh
osa
relat
obes
craniofaci
abnorm
practic
cpap
prescrib
children
complex
osa
due
anatom
structur
abnorm
upper
airway
craniofaci
malform
syndrom
prader
willi
syndrom
morbid
obes
bipap
indic
nocturn
hypoventil
persist
despit
optim
cpap
cpap
associ
improv
sleep
paramet
ahi
ga
exchang
attent
deficit
behavior
sleepi
qualiti
life
less
consensu
regard
type
investig
criteria
bipap
initi
children
neuromuscular
diseas
first
bipap
may
justifi
without
sleep
studi
child
present
episod
acut
respiratori
failur
trigger
respiratori
infect
anesthet
procedur
event
marker
insuffici
respiratori
reserv
concern
time
sleep
studi
lack
valid
recommend
may
partial
explain
heterogen
neuromuscular
disord
children
symptom
suggest
sleepdisord
breath
use
predictor
marker
nocturn
hypoventil
differ
neuromuscular
children
without
document
nocturn
hypoventil
concern
predict
valu
lung
function
respiratori
paramet
larg
prospect
studi
children
neuromuscular
disord
identifi
sensit
specif
daytim
lung
function
respiratori
muscl
test
associ
predict
nocturn
cipp
xvi
abstract
hypoxemia
hypercapnia
type
neuromuscular
disord
thu
taken
account
nocturn
hypoventil
occur
preferenti
disord
character
promin
diaphragmat
weak
children
myopathi
thu
screen
systemat
sleep
disord
breath
priorit
screen
also
recommend
infant
young
children
congenit
myopathi
rapidli
progress
neuromuscular
diseas
children
neuromuscular
diseas
document
nocturn
hypoventil
mean
polysomnographi
recommend
essenti
prior
start
bipap
isol
abnorm
nocturn
ga
exchang
may
suffici
inde
patient
neuromuscular
diseas
thorac
deform
isol
nocturn
hypercapnia
without
daytim
hypercapnia
progress
overt
daytim
respiratori
failur
within
period
year
moreov
presenc
abnorm
overnight
ga
exchang
record
full
polysomnographi
criteria
use
defin
nocturn
hypoventil
highli
variabl
practic
consequ
long
term
niv
indic
reli
upon
hypoventil
detect
score
polysomnographi
patient
neuromuscular
diseas
requir
specif
expertis
inde
instead
apneic
hypopn
event
patient
may
present
progress
simultan
decreas
airflow
thorac
abdomin
movement
accompani
chang
ga
exchang
suggest
global
inspiratori
muscl
weak
paradox
breath
opposit
phase
thorac
abdomin
belt
may
consequ
diaphragmat
dysfunct
weak
intercost
muscl
fals
interpret
obstruct
event
clinic
practic
period
reduc
ventil
paradox
breath
obstruct
andor
central
apneahypopnea
especi
rapidey
movement
sleep
associ
puls
oximetri
spo
andor
transcutan
carbon
dioxid
ptcco
valu
mmhg
indic
insuffici
respiratori
muscl
perform
justifi
long
term
bipap
children
neuromuscular
diseas
clinic
practic
howev
mani
children
progress
neuromuscular
diseas
spinal
muscular
atrophi
duchenn
muscular
dystrophi
start
niv
empir
inde
limit
access
sleep
studi
delay
access
patient
effect
treatment
import
requisit
patient
follow
pediatr
team
expertis
niv
consensu
regard
clinic
situat
criteria
justifi
initi
bipap
children
cystic
fibrosi
like
adult
patient
chronic
obstruct
pulmonari
diseas
bipap
recommend
first
line
treatment
acut
hypercapn
respiratori
exacerb
without
evid
prospect
random
studi
bipap
also
larg
prescrib
patient
lung
transplant
list
insuffici
improv
oxygen
therapi
contrast
recent
cochran
review
conclud
improv
nocturn
ga
exchang
less
oxygen
desatur
respiratori
muscl
fatigu
chest
physiotherapi
proven
benefit
bipap
cystic
fibrosi
conclus
screen
least
overnight
ga
exchang
record
detect
nocturn
hypoxemia
andor
hypercapnia
possibl
complet
sleep
studi
prioriti
children
upper
airway
obstruct
type
neuromuscular
lung
diseas
may
associ
nocturn
hypoventil
symptom
sleepdisord
breath
insuffici
sensit
specif
tend
appear
late
cours
differ
diseas
poor
sleep
qualiti
associ
neurocognit
dysfunct
abnorm
behavior
decreas
qualiti
life
trial
one
three
month
niv
thorough
evalu
niv
period
seem
reason
option
long
term
niv
extrem
efficaci
respiratori
support
transform
scope
chronic
respiratori
failur
sever
sleep
ncpap
common
modal
niv
larg
random
control
trial
rct
conclud
earli
ncpap
safe
altern
immedi
intub
even
extrem
low
birth
weight
elbw
infant
initi
treatment
rd
center
use
ncpap
escal
nippv
intub
use
nippv
initi
mode
non
invas
support
recent
metaanalysi
includ
ten
trial
enrol
total
infant
show
significantli
reduc
risk
meet
respiratori
failur
criteria
risk
ratio
rr
confid
interv
ci
need
intub
typic
rr
ci
among
infant
treat
earli
nippv
compar
earli
ncpap
metaanalysi
demonstr
reduct
risk
cld
among
infant
random
nippv
typic
rr
ci
evid
harm
author
conclud
earli
nippv
appear
superior
ncpap
alon
decreas
respiratori
failur
need
intub
endotrach
tube
ventil
among
preterm
infant
rd
synchron
nippv
vs
ncpap
later
use
post
extub
rd
resolut
bridg
spontan
unsupport
breath
shown
effect
ncpap
updat
metaanalysi
show
nippv
reduc
incid
extub
failur
need
reintub
within
hour
one
week
effect
ncpap
howev
effect
cld
mortal
synchron
may
import
deliv
effect
nippv
devic
use
deliv
nippv
may
import
howev
data
insuffici
support
strong
conclus
synchron
nippv
may
effect
ncpap
also
apnea
prematur
metaanalysi
regard
apnea
prematur
suggest
synchron
nippv
efficaci
apnea
frequent
sever
howev
studi
perform
address
shortterm
outcom
could
address
properli
rate
reintub
thu
studi
need
recommend
synchron
nippv
standard
care
apnea
prematur
possibl
addit
effect
nippv
compar
ncpap
relat
synchron
debat
one
studi
stabl
prematur
infant
find
benefit
synchron
yet
infant
stabl
expos
studi
mode
short
time
noninvas
ventil
probabl
safe
success
depend
gestat
age
data
indic
surfact
may
still
signific
role
treatment
rd
especi
elbw
infant
recent
studi
report
intub
rate
ncpap
group
elbw
infant
lead
us
non
less
invas
mode
surfact
administr
may
allow
infant
benefit
surfact
niv
includ
intub
surfact
extub
insur
approach
minim
invas
surfact
therapi
mist
use
mist
surfact
appli
trachea
without
endotrach
intub
use
thin
cathet
spontan
breath
preterm
infant
receiv
ncpap
techniqu
report
reduc
need
mechan
ventil
ongo
trial
inhal
surfact
consensu
yet
mode
non
invas
surfact
administr
superior
best
time
applic
mode
infant
niv
summar
ncpap
still
common
mode
non
invas
respiratori
support
world
wide
avail
evid
support
prefer
earli
later
use
nippvsnippv
compar
ncpap
minim
use
length
endotrach
ventil
new
mode
niv
nava
nasal
high
frequenc
ventil
need
studi
conclud
benefit
short
long
term
cochran
metaanalysi
examin
risk
benefit
earli
niv
versu
earli
nasal
cpap
preterm
infant
risk
respiratori
distress
within
first
hour
birth
ten
trial
enrol
total
infant
met
criteria
inclus
analysi
author
conclud
earli
niv
appear
superior
nasal
cpap
decreas
respiratori
failur
need
intub
endotrach
tube
ventil
preterm
infant
respiratori
distress
syndrom
larger
trial
howev
need
confirm
result
assess
safeti
niv
compar
nasal
cpap
anoth
cochran
metaanalysi
team
focus
use
niv
deliv
nasal
prong
nasopharyng
tube
extub
preterm
newborn
ten
random
quasirandom
trial
enrol
total
infant
includ
analysi
author
conclud
overal
evid
indic
niv
reduc
incid
extub
failur
need
reintub
within
first
week
effect
nasal
cpap
addit
use
synchron
form
niv
may
import
although
necessit
confirm
larger
trial
similarli
use
mechan
ventil
deliv
niv
appear
effici
bilevel
devic
although
larger
trial
need
confirm
final
differ
niv
nasal
cpap
rate
bronchopulmonari
dysplasia
death
necrot
enterocol
two
public
two
differ
team
summar
data
anim
model
investig
clinic
observ
use
nasal
high
frequenc
oscillatori
ventil
nhfov
neonat
nasal
hfov
advantag
highfrequ
ventil
need
synchron
high
efficaci
remov
co
nasal
cpap
noninvas
interfac
improv
oxygen
via
increas
function
residu
capac
data
preterm
lamb
suggest
nhfov
decreas
incid
bronchopulmonari
dysplasia
addit
report
sever
case
seri
shown
nhfov
use
human
neonat
appar
benefit
compar
niv
modal
author
underlin
sever
survey
report
nhfov
increasingli
attempt
neonatolog
center
random
control
studi
rapidli
need
confirm
nhfov
truli
benefici
human
neonat
mortamet
et
al
assess
avail
interfac
deliv
niv
children
acut
respiratori
failur
given
niv
acut
set
must
initi
rapidli
use
around
clock
sever
day
choic
optim
interfac
crucial
often
make
differ
niv
success
failur
author
summar
advantag
limit
variou
interfac
avail
children
includ
approach
choos
optim
interfac
monitor
toler
cochran
metaanalysi
examin
use
niv
acut
asthma
children
two
trial
enrol
total
children
elig
includ
analysi
bipap
devic
compar
standard
care
use
nasal
cpap
howev
two
studi
asthma
symptom
score
significantli
decreas
low
number
children
high
risk
bia
studi
allow
confirm
reject
benefici
effect
niv
children
acut
asthma
home
niv
focu
two
excel
comprehens
updat
longterm
home
niv
may
indic
central
respiratori
drive
anomali
respiratori
musclethorac
wall
dysfunct
upper
airway
obstruct
andor
primari
bronchopulmonari
disord
markedli
disabl
longterm
basi
amen
cpap
therapi
articl
underlin
contrast
exponenti
use
niv
children
age
worldwid
lack
valid
criteria
especi
initi
titrat
monitor
treatment
challeng
face
longterm
home
niv
infant
children
numer
success
depend
highli
special
multidisciplinari
center
among
other
choic
interfac
patient
mechan
ventil
crucial
factor
addit
train
caregiv
well
avail
dedic
homecar
personnel
asneed
basi
support
caregiv
essenti
alreadi
allud
choos
interfac
ventil
patient
one
challeng
aspect
niv
pediatr
especi
infant
recent
articl
address
problem
optim
interfac
use
innov
technolog
subject
mean
age
year
technolog
studi
includ
imag
assess
fit
particular
mask
patient
face
measur
skin
hydrat
interfac
high
definit
color
photographi
visual
earli
skin
compromis
present
studi
patient
skin
injuri
shown
reduc
use
silicon
foam
dress
interpos
plastic
mask
skin
sign
injuri
observ
water
vaporperm
cloth
mask
use
accompani
editori
underlin
need
intens
research
focus
ideal
niv
interfac
comfort
adapt
wide
rang
facial
shape
ii
prevent
overhydr
skin
iii
prevent
unintent
leak
increas
dead
space
patientventil
asynchroni
esophag
insuffl
ga
niv
lead
gastric
dilat
vast
major
case
cf
easi
diagnos
constel
suggest
clinic
phenotyp
rais
sweat
chlorid
mmoll
two
recogn
diseasecaus
mutat
allow
diagnosi
confirm
treatment
initi
screen
offer
close
famili
member
mani
part
world
newborn
screen
program
case
diagnos
earli
infanc
commonli
base
find
rais
immunoreact
trypsinogen
irt
follow
cftr
genotyp
repeat
irt
number
differ
algorithm
exist
howev
later
life
newborn
period
diagnost
dilemma
aris
addit
test
may
need
exampl
case
provid
use
framework
illustr
issu
old
man
present
primari
care
seek
fertil
test
found
azosperm
question
well
throughout
childhood
suffer
prolong
bout
ct
scan
reveal
moder
bilater
upper
lobe
bronchiectasi
diagnosi
latepres
cf
sensibl
consid
repeat
sweat
test
reveal
chlorid
mmoll
first
line
genet
test
show
heterozyg
mutat
underw
nasal
potenti
differ
test
reveal
normal
basal
pd
almost
complet
absenc
chlorid
secret
upon
stimul
combin
zerochlorid
ringer
camp
agonist
isoprenalin
sensit
test
cftr
function
airway
epithelium
subsequ
found
possess
addit
mutat
allel
mutat
variabl
clinic
signific
often
found
associ
cflike
diseas
one
organ
normal
borderlin
sweat
test
patient
constel
sign
cftrrelat
test
consid
support
diagnosi
cf
well
old
babi
girl
refer
follow
posit
newborn
screen
cf
follow
rais
irt
genotyp
confirm
latter
mutat
ci
lead
residu
variabl
cftr
function
togeth
diseasecaus
mutat
may
lead
cf
albeit
usual
milder
phenotyp
may
also
found
complet
healthi
individu
babi
wellgrown
normal
stool
parent
concern
cf
therefor
allornoth
diseas
consid
learn
cftr
recogn
much
remain
unknown
mani
cftr
mutat
lead
variabl
consequ
may
addit
factor
environ
behavior
aspect
genet
make
socal
modifi
gene
determin
whether
peopl
remain
healthi
display
manifest
diseas
nasal
potenti
differ
test
assay
cftr
function
short
circuit
current
rectal
biopsi
recent
cultur
organoid
latter
may
prove
use
diagnost
aid
case
borderlin
diagnost
test
context
singl
organ
diseas
nasal
polyp
term
cftrrelat
disord
diagnost
understand
evolv
new
term
cfspid
requir
cohort
patient
describ
cflike
diseas
actual
mutat
enac
investig
consid
case
new
insight
cftrdefici
pig
ferret
recapitul
patholog
featur
human
cf
lung
diseas
reveal
airway
inflamm
newborn
anim
absenc
infect
howev
grow
bodi
evid
cftr
defici
impair
critic
innat
immun
function
enabl
lung
infect
cftr
directli
affect
airway
innat
immun
via
function
regul
anion
channel
cftr
regul
chlorid
efflux
also
bicarbon
thiocyan
efflux
cftr
defici
result
loss
bicarbon
acid
airway
surfac
milieu
box
cytokin
alarmin
activ
rage
receptor
significantli
inhibit
macrophag
phagocytosi
bacteri
kill
pseudomona
pneumonia
mous
model
furthermor
alarmin
calgranulin
releas
neutrophil
activ
rage
proinflammatori
signal
via
activ
ne
degrad
iron
contain
protein
lactoferrin
airway
releas
nonhem
iron
requir
bacteri
growth
biofilm
format
also
taken
epitheli
cell
gener
oxid
stress
larg
number
inflammatori
target
lead
sustain
infect
inflamm
enorm
challeng
develop
antiinflammatori
therapi
patient
cf
great
hope
drug
correct
andor
potenti
normal
cftr
function
abrog
cycl
infect
inflamm
start
earli
life
howev
although
ivacaftor
therapi
patient
mutat
significantli
improv
lung
function
weight
gain
sweat
chlorid
level
decreas
airway
inflammatori
mediat
result
may
due
initi
therapi
bronchiectasi
establish
patient
ivacaftor
approv
infant
concept
test
correct
cftr
prevent
infect
inflamm
importantli
earli
prospect
random
doubl
blind
studi
use
oral
glucocorticoid
everi
day
year
patient
cf
provid
proof
principl
antiinflammatori
therapi
improv
lung
function
cf
patient
howev
side
effect
chronic
glucocorticoid
therapi
prevent
use
routin
antiinflammatori
agent
approv
antiinflammatori
therapi
cf
current
high
dose
ibuprofen
azithromycin
although
ibuprofen
slow
lung
function
declin
random
control
prospect
trial
year
particularli
patient
chronic
p
aeruginosa
infect
wide
accept
due
difficulti
obtain
level
monitor
therapi
potenti
side
effect
thrice
weekli
azithromycin
therapi
chronic
p
aeruginosa
wide
accept
therapi
reveal
modest
improv
decreas
risk
pulmonari
exacerb
decreas
serum
inflammatori
marker
chronic
azithromycin
therapi
patient
cf
infect
p
aeruginosa
also
decreas
frequenc
pulmonari
exacerb
cough
improv
sinc
approv
ibuprofen
azithromycin
sever
trial
antiinflammatori
therapi
patient
cf
target
specif
inflammatori
mediat
proteas
reactiv
oxygen
speci
neutrophil
chemoattract
abnorm
intracellular
signal
abnorm
lipid
date
none
drug
move
forward
phase
trial
addit
target
therapi
global
anti
help
assess
appropri
cpap
pressur
achiev
optim
ventil
homogen
thu
prevent
risk
reintub
measur
tensiontim
index
diaphragm
respiratori
muscl
ttdi
ttmu
abl
predict
extub
outcom
howev
sensit
specif
simpl
factor
mainli
gestat
age
birth
weight
perform
similarli
predict
extub
failur
low
preextub
pco
also
show
potenti
predict
extub
success
fail
extub
newborn
neonat
intens
care
set
alway
repres
high
risk
situat
may
associ
signific
deterior
child
even
lead
cardiopulmonari
instabl
death
use
earli
system
steroid
extrem
preterm
infant
recommend
may
compromis
brain
develop
neurosi
studi
infant
gestat
age
week
day
week
day
randomli
assign
earli
within
hour
birth
inhal
budesonid
placebo
longer
requir
oxygen
positivepressur
support
reach
postmenstru
age
week
day
primari
outcom
death
bpd
studi
conclud
among
extrem
preterm
infant
incid
bpd
lower
among
receiv
earli
inhal
budesonid
among
receiv
placebo
advantag
may
gain
expens
increas
mortal
recent
metaanalysi
shinwel
et
al
assess
safeti
efficaci
inhal
corticosteroid
prevent
treatment
bpd
death
preterm
infant
inhal
corticosteroid
associ
signific
reduct
death
bpd
week
postmenstru
age
risk
ratio
rr
confid
interv
ci
p
trial
n
bpd
significantli
reduc
rr
ci
trial
n
use
system
steroid
significantli
reduc
treat
infant
conclud
preterm
infant
appear
benefit
inhal
corticosteroid
reduc
risk
bpd
effect
death
morbid
advers
event
data
longterm
respiratori
growth
development
outcom
eagerli
await
role
inhal
corticosteroid
establish
bpd
spontan
breath
infant
studi
kugelman
et
al
administ
inhal
steroid
hydrofluoalkanebeclomethason
dipropion
qvar
uniqu
small
particl
size
result
cipp
xvi
abstract
higher
lung
deposit
doubleblind
random
placebocontrol
multicent
pilot
studi
studi
unabl
detect
goal
gentl
support
minim
invas
respiratori
therapi
improv
long
term
respiratori
neurolog
outcom
prematur
infant
recent
studi
incorpor
new
modal
respiratori
support
revisit
definit
bpd
object
studi
identifi
optim
definit
bpd
best
predict
respiratori
neurodevelopment
outcom
preterm
infant
conclud
defin
bpd
use
oxygen
alon
inadequ
oxygenrespiratori
support
better
indic
chronic
respiratori
insuffici
particular
oxygenrespiratori
support
week
post
menstrual
age
pma
identifi
best
predictor
seriou
respiratori
morbid
also
display
good
abil
predict
neurosensori
morbid
month
conclud
trend
modern
neonatolog
gentl
possibl
use
new
technolog
mode
therapi
achiev
goal
infant
reveal
infant
titrat
lower
satur
rang
greater
mortal
rate
infant
assign
rang
contrast
cot
studi
reveal
differ
mortal
low
high
satur
rang
arm
studi
given
concern
increas
mortal
rais
support
boost
trial
current
consensu
titrat
therapi
oxyhemoglobin
satur
low
rang
prevent
potenti
increas
risk
infant
death
still
remain
mani
clinic
uncertainti
concern
diagnosi
bpd
risk
chronic
lung
diseas
first
diagnosi
bpd
base
level
supplement
oxygen
ventilatori
support
week
gestat
age
current
debat
concern
whether
diagnost
criteria
determin
optim
gestat
age
predict
futur
respiratori
diseas
second
although
much
stronger
data
concern
perinat
factor
increas
risk
bpd
still
uncertainti
concern
infant
develop
chronic
lung
diseas
mandat
continu
follow
infant
recruit
larg
cohort
studi
intern
insight
gain
discov
postnat
factor
either
confer
greater
risk
may
mitig
sever
futur
lung
diseas
third
bpd
rel
rare
diseas
variabl
phenotyp
therefor
larg
number
subject
multicent
clinic
trial
requir
definit
test
new
therapi
determin
whether
decreas
bpd
chronic
lung
diseas
rais
import
issu
need
establish
bpd
endotyp
better
inform
therapeut
trial
target
specif
pathway
investig
underway
identifi
host
factor
genet
epigenet
associ
transcriptom
metabolom
microbiom
profil
associ
risk
bpd
chronic
lung
diseas
deform
anterior
chest
wall
dacw
distribut
spectrum
morpholog
sever
symmetri
associ
abnorm
thu
deform
may
occur
sternum
protrud
posteriorli
pectu
excavatum
forwardli
pectu
carinatum
find
like
pouter
pigeon
deform
poland
syndrom
sternal
cleft
associ
dacw
cover
present
quit
differ
pathophysiolog
treatment
pectu
excavatum
may
present
birth
often
seen
consid
inher
radiosensit
popul
attempt
avoid
exposur
radiat
advers
effect
research
group
develop
imag
reconstruct
methodolog
similar
obtain
ct
use
magnet
reson
andor
laser
scanner
without
radiat
could
replac
ct
preoper
approach
patient
physic
exercis
may
play
role
correct
postur
attenu
deform
develop
certain
muscl
group
especi
case
slight
deform
seri
recommend
train
use
row
cano
shown
encourag
result
treatment
mild
pectu
excavatum
howev
highlight
physic
exercis
per
se
name
swim
treatment
pectu
excavatum
structur
prosthes
implant
year
remov
treatment
complet
esthet
result
goodexcel
case
regard
open
procedur
advantag
discreet
cutan
incis
rather
incis
anterior
chest
wall
oper
time
classic
present
pectu
carinatum
protrus
lower
third
sternum
maxim
promin
xiphostern
junction
may
quit
evid
case
narrow
laterallater
diamet
thorax
rib
protrud
anteriorli
less
curvatur
usual
sternum
may
rotat
due
differ
costal
growth
rate
two
hemithorax
less
frequent
pectu
carinatum
present
unilater
protrus
costal
cartilag
associ
rotat
sternum
opposit
side
like
pectu
excavatum
occur
sporad
mani
patient
rel
histori
dacw
type
may
also
part
connect
tissu
syndrom
diseas
classic
treatment
began
surgic
usual
modif
ravitch
procedur
still
use
case
mark
deform
current
first
line
conserv
treatment
babi
antenat
ctm
undergo
chest
radiograph
soon
birth
low
sensit
high
resolut
comput
tomographi
hrct
contrast
delin
vasculatur
current
goldstandard
investig
surgeri
plan
optim
time
unclear
given
ctm
regress
first
one
two
year
life
uncertainti
best
must
share
honestli
famili
one
right
answer
asymptomat
child
need
acknowledg
follow
obtain
natur
histori
data
recom
inflammatori
cell
infiltr
n
ppb
risk
malign
transform
reduc
elimin
surgeri
ppb
describ
complet
resect
ctm
tumor
marker
found
excis
ctm
may
associ
malign
includ
echinoderm
microtubuleassoci
proteinlik
anaplast
lymphoma
kinas
alk
fusiontyp
oncoprotein
erythroblast
leukemia
viral
oncogen
homologu
kra
risk
rare
devast
complic
air
travel
small
unquantifi
risk
complic
air
travel
devast
fatal
cerebrovascular
accid
describ
patient
well
child
safe
small
risk
surgic
complic
taken
togeth
view
risk
outweigh
elect
surgeri
skill
hand
answer
question
pose
titl
ye
howev
mani
would
disagre
better
mean
assess
risk
complic
present
unsatisfactori
state
affair
like
continu
place
ctm
patient
high
low
risk
categori
may
feasibl
algorithm
incorpor
radiolog
featur
mutat
analysi
radiolog
featur
suggest
uncompl
ctm
includ
antenat
detect
presenc
system
feed
vessel
hyperinfl
lung
featur
suggest
ppb
includ
bilater
multiseg
involv
although
larg
studi
patient
group
algorithm
use
caution
prospect
valid
anoth
cohort
ct
featur
overlap
ctmsequestr
ppb
although
presenc
feed
vessel
hyperinfl
lung
ctmsequestr
bilater
multiseg
involv
ppb
report
help
distinguish
featur
famili
histori
tumor
ppb
lung
cyst
renal
anomali
close
rel
childhood
malign
especi
wilm
tumor
medulloblastoma
suggest
enhanc
likelihood
mass
ppb
hope
futur
work
includ
molecular
test
tumor
marker
allow
risk
stratif
target
surgeri
highrisk
children
plastic
bronchiti
rare
disord
character
format
firm
branch
cast
fill
airway
firm
branch
cast
differ
sputum
plug
seen
patient
low
dose
macrolid
report
effect
patient
although
respons
inconsist
inhal
tissu
plasminogen
activ
tpa
breakdown
cast
format
also
caus
airway
inflamm
recommend
regular
therapi
proven
role
acetylcystein
dornas
alfa
hyperton
salin
bronchodil
asthma
medic
treat
plastic
bronchiti
definit
therapi
patient
lymphat
plastic
bronchiti
consist
pulmonari
lymphat
map
ablat
aberr
vessel
produc
signific
relief
often
appear
cure
plastic
bronchiti
center
lymphat
map
ablat
readili
avail
aggress
thorac
duct
ligat
also
proven
help
mani
case
asthma
obes
increas
preval
compar
set
similar
period
time
tempt
specul
must
direct
link
two
howev
associ
two
phenomena
way
impli
way
relat
far
less
one
caus
howev
number
cross
section
longitudin
studi
establish
posit
associ
asthmawheez
high
bodi
mass
usual
express
bodi
mass
index
bmi
kgm
either
continuum
usual
use
accept
categor
threshold
overweight
obes
sever
possibl
explan
associ
includ
revers
causat
respiratori
symptom
overweight
confound
one
independ
variabl
includ
share
genet
factor
associ
high
bodi
mass
wheez
ill
mechan
effect
bodi
fat
distribut
respiratori
function
play
chanc
infant
growth
could
play
relationship
either
direct
link
earli
bodi
size
growth
later
obes
mechan
associ
rapid
growth
earli
childhood
lung
function
develop
rais
question
signific
rapid
earli
growth
could
marker
intrauterin
advers
even
birth
weight
nomin
normal
rang
ie
growth
retard
infant
birth
weight
could
featur
variat
infant
nutrit
practic
cross
section
studi
major
cross
section
studi
obes
asthma
report
posit
associ
overal
suggest
obes
girl
stronger
associ
asthma
male
counterpart
howev
consider
heterogen
sexstratifi
risk
individu
studi
systemat
review
sex
modif
associ
obes
incid
asthma
children
report
stronger
effect
boy
girl
recent
cross
section
evid
suggest
fat
distribut
play
role
associ
central
obes
associ
asthma
also
report
associ
obes
stronger
nonallerg
compar
allerg
asthma
howev
also
suggest
link
high
bodi
mass
children
atop
sensit
therefor
although
cross
section
evid
support
associ
potenti
mechan
highli
uncertain
longitudin
studi
six
longitudin
studi
children
year
old
met
inclus
criteria
recent
systemat
review
prospect
associ
obes
asthma
diagnosi
least
year
cipp
xvi
abstract
measur
bmi
diagnosi
asthma
obes
overweight
various
consid
bmi
th
centil
sex
age
bmi
zscore
major
describ
posit
associ
discord
sexstratifi
risk
individu
studi
combin
effect
estim
show
posit
associ
overweight
th
centil
bmi
obes
th
centil
bmi
asthma
result
consist
earlier
find
adult
men
women
analyz
detail
growth
data
children
birth
year
use
linear
spline
look
differ
part
growth
trajectori
found
rapid
weight
gain
birth
month
associ
later
asthma
diagnosi
bronchial
hyperrespons
impact
earli
postnat
growth
asthma
could
mediat
causal
associ
obes
asthma
later
childhood
infant
size
rate
weight
gain
infanc
associ
obes
later
age
infant
obes
measur
varieti
differ
metric
includ
bmi
th
centil
cohort
casecontrol
studi
show
consist
associ
obes
outcom
rang
age
across
lifecours
preschool
late
adulthood
also
major
studi
rapid
weight
gain
infanc
measur
differ
period
show
posit
associ
later
childhood
adolesc
obes
anoth
possibl
explan
report
link
rapid
postnat
growth
lower
lung
function
infanc
beyond
small
airway
could
predispos
wheez
symptom
misclassifi
asthma
young
children
altern
rapid
weight
gain
feed
practic
infanc
may
direct
effect
immun
develop
one
major
problem
make
causal
infer
observ
associ
confound
measur
unmeasur
variabl
use
mendelian
random
approach
test
unconfound
associ
bodi
mass
asthma
birth
cohort
children
genet
risk
obes
gener
use
risk
score
base
risk
allel
includ
fto
assumpt
allel
randomli
assort
meiosi
use
instrument
variabl
high
bodi
mass
although
allel
explain
varianc
bmi
popul
found
evid
causal
link
high
bodi
mass
asthma
age
year
cohort
obes
truli
causal
initi
asthma
children
number
mechan
advanc
explain
plausibl
explan
obes
associ
system
inflamm
may
give
rise
airway
inflamm
asthma
evid
adipocyt
sourc
proinflammatori
cytokin
littl
evid
system
inflamm
obes
directli
associ
airway
inflamm
anoth
possibl
link
would
promot
allerg
inflamm
adipokin
effect
immun
system
like
us
other
report
stronger
associ
obes
nonatop
asthma
found
evid
obes
associ
atopi
midchildhood
cohort
specif
asthmaobes
phenotyp
suggest
adult
children
may
associ
increas
asthma
sever
evid
obes
establish
asthma
associ
poor
asthma
control
increas
exacerb
suboptim
respons
glucocorticoid
poor
respons
steroid
may
associ
neutrophilpredomin
airway
inflamm
consist
find
stronger
associ
nonatop
asthma
intrigu
aspect
relationship
obes
respiratori
health
although
obes
independ
risk
factor
condit
asthma
obes
patient
affect
respiratori
diseas
therefor
import
disentangl
true
causal
relationship
mere
associ
consid
triad
obes
system
inflamm
respiratori
diseas
major
research
date
investig
interact
obes
inflamm
respiratori
diseas
children
focus
asthma
updat
explor
relationship
context
asthma
one
biggest
conundrum
face
cipp
xvi
abstract
consid
obes
asthma
although
children
asthma
obes
known
whether
asthmat
children
increas
risk
weight
gain
due
modifi
lifestyl
factor
crosssect
studi
aim
investig
impact
asthma
lifestyl
factor
also
associ
obes
shown
nonobes
children
asthma
greater
sleep
latenc
plasma
triglycerid
compar
nonobes
nonasthmat
children
suggest
asthma
per
se
risk
factor
obes
although
specif
phenotyp
asthma
associ
obes
accept
describ
adult
patient
specif
sever
diseas
adult
onset
predominantli
femal
littl
evid
airway
inflamm
increas
evid
obes
asthma
phenotyp
children
obes
asthma
complex
influenc
numer
factor
includ
nutrit
impact
gut
lung
microbiom
metabol
airway
wall
mechan
genet
suscept
system
inflamm
key
differ
adult
onset
pediatr
obes
asthma
phenotyp
role
matern
weight
pregnanc
rate
child
weight
gain
earli
postnat
life
matern
obes
associ
childhood
asthma
associ
alter
immun
profil
cord
blood
includ
switch
toward
proinflammatori
cytokin
includ
tnfalpha
interestingli
proinflammatori
state
associ
increas
expect
allerg
inflammatori
mediat
inde
number
eosinophil
cell
lower
babi
born
obes
mother
underscor
like
fundament
differ
pathophysiolog
childhood
onset
obes
asthma
allerg
asthma
specif
system
inflammatori
profil
recent
describ
adult
obes
patient
high
phenotyp
system
inflamm
clinic
featur
metabol
dysfunct
occur
commonli
subset
obes
asthma
patient
associ
sever
asthma
data
togeth
cord
blood
data
matern
obes
suggest
mechan
underpin
obes
asthma
adult
children
may
similar
potenti
central
mediat
drive
diseas
furthermor
absenc
inflammatori
profil
may
explain
obes
asthma
rel
steroid
resist
phenotyp
experiment
studi
also
shown
although
steroid
may
help
reduc
allergeninduc
compon
airway
inflamm
mice
fed
high
fat
diet
expos
hous
dust
mite
second
independ
inflammatori
compon
includ
macrophag
marker
type
inflamm
persist
import
point
consid
assess
inflamm
associ
asthma
relev
tissu
specif
inflamm
versu
system
inflamm
crosstalk
airway
structur
cell
inflammatori
cell
key
determin
protect
patholog
consequ
may
relev
context
obes
asthma
sinc
evid
suggest
locat
eosinophil
differ
tissu
crucial
determin
effect
lung
specif
airway
wall
caus
inflamm
yet
locat
viscer
fat
improv
glucos
homeostasi
clinic
data
correl
lung
tissu
eosinophilia
obes
may
therefor
shed
light
role
eosinophil
obes
individu
asthma
improv
treatment
patient
respons
critic
compon
grow
preval
obes
western
world
shift
toward
diet
high
fat
content
low
fiber
direct
impact
low
fiber
diet
specif
low
short
chain
fatti
acid
scfa
composit
gut
microbiom
metabolit
microbiota
shown
influenc
develop
allerg
airway
diseas
dietari
fiber
content
chang
composit
gut
lung
microbiota
gut
microbiota
metabol
fiber
increas
concentr
circul
scfa
therefor
mice
fed
highfib
diet
increas
circul
level
scfa
protect
allerg
inflamm
lung
wherea
lowfib
diet
decreas
level
scfa
increas
allerg
airway
diseas
addit
low
inflamm
addit
explan
rel
poor
respons
obes
asthma
steroid
may
presenc
alter
airway
mechan
obes
children
consist
shown
low
ratio
obstruct
pictur
may
explain
suscept
develop
sever
asthma
recent
find
report
relat
lung
structur
obes
children
presenc
airway
dysanapsi
airway
dysanapsi
describ
physiolog
incongru
mismatch
develop
lung
parenchyma
size
specif
calib
length
airway
reflect
presenc
abnorm
ratio
despit
presenc
normal
valu
fvc
airway
dysanapsi
present
obes
children
without
asthma
consist
longitudin
measur
obes
present
howev
children
obes
asthma
presenc
dysnapsi
clinic
impact
manifest
sever
exacerb
increas
use
system
steroid
impact
weight
loss
respiratori
health
inflammatori
statu
sustain
weight
loss
use
dietari
lifestyl
modif
difficult
reveal
conclus
result
impact
asthma
control
inflammatori
statu
date
children
primarili
inabl
sustain
weight
loss
howev
impact
bariatr
surgeri
asthma
system
inflamm
investig
adult
obes
asthma
highlight
complex
relationship
obes
system
inflamm
asthma
adult
obes
asthma
low
ige
improv
airway
hyperrespons
ahr
weight
loss
chang
rest
airway
resist
contrast
obes
asthma
high
ige
improv
airway
mechan
resist
chang
ahr
weight
loss
data
suggest
least
cipp
xvi
abstract
phenotyp
obes
asthma
distinct
pathophysiolog
contribut
allergi
obes
exist
challeng
children
disentangl
phenotyp
target
treatment
accordingli
allerg
obes
asthma
phenotyp
perhap
acquir
phenotyp
relat
predominantli
diet
lifestyl
may
benefit
aggress
weight
loss
measur
may
becom
respons
steroid
impact
alter
airway
mechan
remov
second
group
nonallerg
predominantli
system
inflammatori
phenotyp
may
driven
like
predomin
genet
suscept
obes
asthma
may
benefit
aggress
weight
loss
measur
system
antiinflammatori
agent
antibodi
mount
evid
associ
obes
asthma
children
increas
preval
howev
pathogenesi
link
two
condit
complex
multifactori
obes
caus
varieti
mechan
metabol
immunolog
chang
airway
system
circul
significantli
impact
clinic
asthma
control
pathway
lead
reduc
sensit
steroid
molecular
mechan
drive
obes
asthma
uncov
suggest
presenc
two
pathophysiolog
phenotyp
within
obes
asthma
high
allerg
phenotyp
like
reflect
inher
suscept
ahr
ad
acquisit
obes
low
nonallerg
phenotyp
may
reflect
suscept
obes
associ
airway
dysnapsi
obstruct
airway
diseas
studi
confirm
phenotyp
children
investig
efficaci
phenotyp
specif
treatment
approach
need
help
tackl
challeng
obes
inflamm
asthma
worldwid
obes
epidem
respons
signific
respiratori
problem
children
adult
typic
observ
chronic
respiratori
problem
consequ
obes
respir
pronounc
sleep
present
short
updat
focus
respiratori
consequ
obes
sleep
children
adolesc
nevertheless
first
briefli
summar
overal
consequ
obes
lung
function
necessari
complet
understand
sleep
disord
breath
obes
children
consist
effect
obes
lung
function
decreas
function
residu
capac
morbid
obes
approach
residu
volum
decreas
function
residu
capac
due
mass
load
lung
adipos
tissu
abdomen
well
thorac
caviti
around
rib
cage
consequ
rest
ventil
take
place
lower
lung
volum
tether
action
elast
parenchyma
alveoli
intrapulmonari
bronchi
reduc
lead
turn
deleteri
consequ
follow
first
low
lung
volum
decreas
lung
complianc
increas
work
breath
secondli
decreas
function
residu
capac
decreas
pulmonari
oxygen
store
increas
risk
bronchial
closur
tidal
breath
especi
lower
pulmonari
region
consequ
ventilationperfus
mismatch
frequent
region
perfus
predomin
explain
frequent
mild
hypoxemia
observ
obes
summari
bronchopulmonari
consequ
obes
increas
work
breath
favor
mild
hypoxemia
even
rest
wake
even
absenc
signific
sleeprel
upper
airway
obstruct
deleteri
effect
obes
lung
function
tend
pronounc
night
inde
recumb
posit
hyperpress
diaphragm
lower
pulmonari
region
due
increas
abdomin
fat
mass
highest
addit
sleep
normal
associ
alter
breath
loss
cipp
xvi
abstract
wake
stimulu
breath
decreas
upper
airway
thorac
respiratori
muscl
activ
especi
rem
sleep
obes
import
risk
factor
sleepdisord
breath
sdb
least
obes
children
potenti
sdb
addit
sever
sdb
proport
degre
obes
children
everi
bodi
mass
index
bmi
increment
one
lead
increas
risk
sdb
mechan
sleepdisord
breath
obes
children
found
multipl
first
describ
mechan
effect
adipos
tissu
mass
lung
function
pronounc
supin
posit
secondli
number
mechan
tend
promot
upper
airway
obstruct
explain
high
frequenc
obstruct
sleepdisord
breath
osdb
fatti
infiltr
upper
airway
especi
level
tongu
parapharyng
pad
often
consid
primari
causal
factor
upper
airway
obstruct
howev
magnet
reson
imag
studi
perform
obes
adolesc
found
even
age
adenotonsillar
hypertrophi
remain
main
factor
explain
upper
airway
obstruct
higher
frequenc
malocclus
recent
report
obes
vs
nonobes
children
osdb
obesityrel
decreas
lung
volum
respons
reduc
tension
trachea
upper
airway
turn
consequ
increas
upper
airway
complianc
promot
upper
airway
collaps
viscer
adipos
held
respons
upper
airway
obstruct
via
inflamm
high
metabol
activ
viscer
adipocyt
produc
proinflammatori
mediat
would
lead
among
other
upper
airway
inflamm
vein
osdb
consid
one
manifest
metabol
syndrom
secondari
viscer
adipos
releas
growth
factor
secondari
obesityinsulin
resist
state
may
lead
soft
tissu
edema
upper
airway
final
blunt
respiratori
reflex
ventilatori
respons
co
reduc
ventilatori
drive
especi
upper
airway
dilat
muscl
observ
patient
reduct
ventilatori
drive
seemingli
relat
among
other
resist
leptin
cytokin
hormon
secret
larg
amount
adipocyt
diagnosi
obstruct
sleepdisord
breath
must
made
high
index
suspicion
obes
children
snore
apnea
breath
difficulti
night
frequent
report
histori
take
well
nocturn
enuresi
excess
daytim
sleepi
hyperact
behavior
problem
andor
academ
difficulti
clinic
examin
addit
systemat
investig
system
arteri
hypertens
presenc
risk
factor
osdb
nasal
obstruct
orthodont
anomali
adenotonsillar
hypertrophi
note
necktowaist
ratio
independ
predict
obstruct
sleep
apnea
syndrom
osa
rr
per
unit
valu
propos
screen
test
help
priorit
overweight
obes
children
polysomnographi
usual
laboratori
test
investig
metabol
syndrom
especi
import
diagnost
workup
obes
children
usual
children
diagnos
sever
osdb
strongli
advis
overnight
attend
polysomnographi
prefer
test
establish
diagnosi
osa
howev
long
wait
list
rule
higher
sever
osdb
obes
children
requir
earli
diagnosi
treatment
although
home
sleep
apnea
test
report
viabl
altern
diagnos
pediatr
osa
frequenc
nocturn
hypoventil
obes
children
necessit
perform
co
monitor
addit
recent
result
suggest
overnight
puls
oximetri
clinic
examin
help
predict
osa
obes
children
suggest
clinic
context
beyond
test
seek
establish
diagnosi
osa
druginduc
sleep
sedat
gain
popular
substanti
site
upper
airway
obstruct
guid
surgic
treatment
includ
presenc
obes
whether
test
indic
patient
osdb
persist
follow
adenotonsillectomi
remain
matter
debat
overal
osdb
obes
potenti
yield
frequent
sever
complic
compar
osdb
nonobes
children
cardiovascular
complic
childhood
obes
lead
caus
arteri
hypertens
osdb
accompani
higher
sympathet
activ
reactiv
well
increas
arteri
stiff
howev
recent
metaanalysi
shown
follow
adenotonsillectomi
osa
cure
obes
children
postop
followup
thu
import
detect
residu
osa
ideal
overnight
polysomnographi
addit
obes
children
risk
factor
postop
cardiorespiratori
complic
vs
overnight
hospit
monitor
mandatori
follow
adenotonsillectomi
treatment
option
obes
children
osdb
includ
intens
weight
reduct
program
cpap
exercis
well
bariatr
surgeri
morbidli
obes
adolesc
obesityhypoventil
syndrom
pickwickian
syndrom
defin
associ
bodi
mass
index
kgm
arteri
hypercapnia
wake
sdb
absenc
caus
alveolar
hypoventil
children
obesityhypoventil
syndrom
consid
extrem
osdb
spectrum
lung
physiolog
grossli
impair
due
sever
obes
mark
mechan
load
respiratori
system
respons
increas
work
breath
gross
ventilationperfus
anomali
lead
turn
chronic
hypoxemia
hypercapnia
consequ
increas
bicarbon
resist
leptin
would
respons
abnorm
ventilatori
drive
respons
hypoxia
hypercapnia
obesityhypoventil
syndrom
bear
risk
polycythemia
pulmonari
hypertens
right
ventricular
failur
increas
morbid
mortal
regard
treatment
although
adenotonsillectomi
consid
howev
usual
insuffici
addit
postop
complic
frequent
sever
signific
mortal
risk
cpap
effici
bipap
often
necessari
weight
reduct
also
primari
import
bariatr
surgeri
often
consid
adolesc
